Identificação e classificação de tecidos tumurais da próstata por FTIR by Fernandes, Inês Castro
 Universidade de 
Aveiro 
 
2013 
Secção Autónoma de Ciências da Saúde 
Inês Castro Fernandes 
 
Identificação e classificação de tecidos tumorais da 
próstata por FTIR 
 
Identification and classification of prostate tumour 
tissues by FTIR  
 
 
   
 
 
 
  
Universidade de 
Aveiro 
 
2013  
Secção Autónoma de Ciências da Saúde 
Inês Castro Fernandes 
 
 
Identificação e classificação de tecidos tumorais da 
próstata por FTIR 
 
Identification and classification of prostate tumour 
tissues by FTIR  
  
Tese apresentada à Universidade de Aveiro para cumprimento dos requisitos 
necessários à obtenção do grau de Mestre em Biomedicina Molecular, 
realizada sob a orientação científica da Doutora Carla Alexandra Pina da Cruz 
Nunes, Professora Auxiliar Convidada da Secção Autónoma de Ciências da 
Saúde da Universidade de Aveiro e co-orientação científica da Doutora 
Margarida Sâncio da Cruz Fardilha, Professora Auxiliar Convidada da Secção 
Autónoma de Ciências da Saúde da Universidade de Aveiro. 
 
   
 
 
This work was co-financed by 
Fundação para a Ciência e Tecnologia 
(PTDC/QUI-BIQ/118492/2010) and 
FEDER (FCOMP-01-0124-FEDER-
020895). 
 
 
 
 
 
 
   
  
 
 
 
Dedico este trabalho ao meu pai e à minha mãe, que me proporcionam 
estabilidade e que sempre me apoiaram e incentivaram durante todo o meu 
percurso académico, ao qual só tive o privilégio de ter acesso graças aos seus 
esforços. 
 
“Há sem dúvida quem ame o infinito,  
Há sem dúvida quem deseje o impossível,  
Há sem dúvida quem não queira nada 
Três tipos de idealistas, e eu nenhum deles:  
Porque eu amo infinitamente o finito,  
Porque eu desejo impossivelmente o possível,  
Porque quero tudo, ou um pouco mais, se puder ser,  
Ou até se não puder ser...” 
 
(excerto do poema “O que há em mim é sobretudo cansaço” de Álvaro de 
Campos)  
 
 
“Sou feliz só por preguiça. A infelicidade dá uma trabalheira pior que a doença: 
é preciso entrar e sair dela…” 
 
(Mia Couto) 
 
 
 
 
 
 
   
 
 
 
 
 
 
o júri   
 
presidente Prof. Doutora Odete Abreu Beirão da Cruz e Silva 
professora Auxiliar com Agregação da Secção Autónoma de Ciências da 
Saúde, Universidade de Aveiro 
 
  
 Professora Doutora Ivonne Delgadillo Giraldo 
 professora Associada com Agregação do departamento de química, 
Universidade de Aveiro 
 
  
 Professora Doutora Carla Alexandra Pina da Cruz Nunes 
 professora Auxiliar Convidada da Secção Autónoma de Ciências da Saúde, 
Universidade de Aveiro 
 
 
 
  
  
  
  
  
  
 
 
 
 
 
 
   
  
 
agradecimentos 
 
Um grande agradecimento à Professora Doutora Alexandra Nunes pelo apoio e 
confiança no meu trabalho. Obrigada pelos concelhos e pela orientação sempre 
disponibilidade. 
 
À Professora Doutora Margarida Fardilha, obrigada pela co-orientação, apoio e 
disponibilidade.  
 
À Professora Doutora Odete da Cruz e Silva obrigada pela confiança no projeto. 
 
Ao Grupo de Química dos produtos naturais e alimentares da Universidade de Aveiro, 
em especial à Professora Doutora Ivonne Delgadillo pela disponibilização do FTIR. 
 
Ao Centro de Biologia Celular da Universidade de Aveiro, obrigada pelo material 
disponibilizado. 
 
À Joana Vieira obrigada pela disponibilidade e sugestões.   
 
A todos os pacientes que aceitaram fazer parte deste estudo. 
 
Aos Urologistas António Patrício e Nuno Maio do Hospital Infante Dom Pedro, 
responsáveis pela colheita das amostras, obrigada pela ajuda neste projecto. 
 
À Rafaela, obrigada por me acompanhares durante esta etapa final do nosso percurso 
académico, pela amizade e pelo teu espírito alegre e otimista contagiante.  
 
À Rita, à Sónia, à Rita Ribeiro e à Cindy pela amizade e companheirismo e pelos 
momentos marcantes que partilharam comigo durante o nosso percurso universitário, 
que me ajudaram a crescer e a moldar a pessoa que sou hoje. Obrigada Rita, minha 
companheira de quarto, por todos os bons momentos e rotinas que passamos juntas. 
 
Ao Filipe, obrigada pelo companheirismo e por me fazeres sorrir, pela confiança em 
mim e por me incentivares a trabalhar mais e melhor para realizar os meus objetivos. 
 
A todos os meus colegas de mestrado, obrigada pelo apoio. 
 
A todos os meus amigos, obrigada pela amizade e pelos bons momentos de 
descontração.  
 
 Aos meus pais, obrigada por fazerem de mim a pessoa que sou hoje. Obrigada pelo 
amor e orientação, por sempre acreditarem em mim e estarem sempre do meu lado em 
todas as fases da minha vida.  
 
A toda a minha família, obrigada pelo amor e pela força.   
 
A Deus, que sei que está sempre a olhar por mim.  
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
  
palavras-chave 
 
Cancro da Próstata, espectroscopia de infravermelho, tecidos, tumor, análise multivariada 
 
resumo 
 
 
O desenvolvimento do cancro da próstata (CaP) ainda não é inteiramente compreendido, 
mas já se reconhece que este se desenvolve a partir de estágios pré-malignos. Assim, o 
fator mais importante na prevenção do cancro é a deteção precoce, que facilita a 
erradicação destas células pré-malignas antes de uma invasão sistémica. Há uma grande 
necessidade clínica de técnicas que possam detetar essas alterações bioquímicas pré-
malignas que podem avançar para cancro. 
A espectroscopia de infravermelho é uma poderosa ferramenta analítica para fornecer 
informações detalhadas sobre a composição química de amostras biológicas complexas, 
como tecidos. Esta técnica baseia-se nas vibrações entre os átomos de uma molécula. As 
moléculas absorvem luz infravermelha e dão origem a padrões espectrais distintos de luz 
transmitida. Esta é uma técnica analítica não-destrutiva, altamente sensível e específica que 
permite a identificação de sinais associados ao cancro da próstata ao nível bioquímico, 
proporcionando um melhor diagnóstico e facilitando a identificação de tumores com 
biopotencial agressivo. 
Esta dissertação é um estudo exploratório que pretende testar a capacidade da 
espectroscopia de infravermelho por transformada de Fourier (FTIR) em discriminar 
amostras de CaP de amostras controlo e identificar sinais espectroscópicos relacionados 
com grupos funcionais de compostos bioquímicos presentes nos tecidos malignos. 
Amostras de biópsias prostáticas foram recolhidas de peças de prostatectomia radical de 8 
pacientes caracterizados com antigénio específico da próstata (PSA) elevado e/ou exame 
de toque rectal (TR) anormal. Também foram fornecidas outras informações 
histopatológicas relevantes sobre os pacientes, como o score de Gleason e a classificação 
TNM. Amostras de CaP e controlo foram analisadas por FTIR e os espectros resultantes 
foram submetidos a análise em componentes principais (ACP) nas regiões 3000-2800 cm
-1
, 
1200-900 cm
-1
 e 1800-1700 cm
-1
. 
O diagrama das coordenadas fatoriais (scores) discriminou os espectros das amostras de 
CaP dos espectros das amostras controlo. O diagrama das contribuições fatoriais (loadings) 
permitiu a identificação de sinais espectroscópicos associados a modificações bioquímicas 
patológicas esperadas em tecidos malignos, nomeadamente desregulações no metabolismo 
lipídico, com base num elevado conteúdo em ácidos gordos e em alterações nas cadeias 
lipídicas da membrana; também se verificou um menor conteúdo em polissacarídeos 
(glicose) e em glicogénio e num aumento nos ácidos nucleicos.  
No futuro, novas investigações irão possibilitar o desenvolvimento de um modelo universal 
de classificação multivariada por FTIR para o cancro da próstata. 
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abstract 
 
The development of prostate cancer (PCa) is not yet fully understood, but it is already 
recognized that it develops through pre malignant stages. Thus, the most important factor 
in the prevention of cancer is early detection, facilitating eradication of these pre-
malignant cells prior to systemic invasion. There is a great clinical need for techniques 
that can detect these pre-malignant biochemical changes that can advance to cancer.  
The infrared (IR) spectroscopy is a powerful analytical tool to provide detailed information 
on the chemical composition of complex biological samples, such as tissues. This 
technique is based on the vibrations between the atoms of a molecule. The molecules 
absorb infrared light and give rise to distinctive spectral patterns in transmitted light. This 
is a non-destructive, highly sensitive and specific analytical technique that allows the 
identification of signals associated with prostate cancer at a biochemical level, providing 
an improved diagnosis of cancer and also facilitating the identification of tumors with 
aggressive biopotential.  
This dissertation is an exploratory study that intends to test the ability of the Fourier 
transform infrared spectroscopy (FTIR) to discriminate between control and PCa samples 
and to identify spectroscopic signals related to functional groups of biochemical 
compounds present in the malignant tissues.  
Prostate biopsy samples were collected from radical prostatectomy pieces of 8 patients 
characterized with elevated prostate specific antigen (PSA) and/or abnormal digital rectal 
examination (DRE). Also relevant histopathological information about the patients has 
been provided, including the Gleason grade and the TNM staging. PCa and control 
samples were analysed by FTIR and the resulting spectra were submitted to Principal 
Component Analysis (PCA) in the ranges 3000-2800 cm
-1
, 1200-900 cm
-1
 and 1800-1700 
cm
-1
. 
The diagram of the factorial coordinates (scores) discriminated the spectra of PCa 
samples from the spectra of controls samples. The diagram of the factorial contributions 
(loadings) allowed the identification of spectroscopic signals associated with biochemical 
pathologic modifications expected in malignant tissues, mainly dysregulations in lipid 
metabolism, based on higher content in fatty acids and increased disorder of the chains 
of membrane lipids; also a lower polysaccharide (glucose) and glycogen content and an 
increase in the nucleic acids.  
In the future, further investigations would make possible the development of a universal 
FTIR multivariate classification model for prostate cancer.  
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Chapter one 
This chapter describes the normal anatomy and function of the prostate 
gland. The current diagnostic modalities of prostate cancer are outlined in 
addition to an overview of the prostate cancer epidemiology and aetiology. 
Also an introduction about the technique Fourier Transform Infrared 
Spectroscopy as a new diagnostic modality of prostate cancer and its 
biomedical applications are included in this chapter. To conclude, the aims 
and objectives of this thesis are stated. 
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A. Introduction 
 
1. Prostate Gland 
1.1. Anatomy of the Normal Prostate 
The term ‘prostate’ was first used by Herophilus of Alexandria in 335 B. C. to describe the small 
organ situated in front of the bladder and derived from the Greek word prohistani which means 
"to stand in front of".(1) 
The prostate gland is a small firm organ, about the size of a chestnut, has the shape of a pyramid 
and lies on the pelvic musculofascial floor, located below the bladder and in front of the rectum – 
see Figure 1. 
The prostate is surrounded by a thin, filmy layer of connective tissue, which separates posteriorly 
the prostate and seminal vesicles from the rectum - Denonvilliers’ fascia. Anteriorly, the 
puboprostatic ligaments fix the prostate to the pubic bone, being the gland held in the dorsal vein 
plexus between these structures.(2-4)  It consists of a fibromuscular glandular part and the 
stroma and has a base at the bladder neck and an apex at the urogenital diaphragm, anterior and 
posterior surfaces and two inferior-lateral surfaces. Skeletal muscle fibers from the urogenital 
diaphragm extend into the prostate at the apex and, anteriorly, up to the midprostate. The 
urethra passes from the bladder and through the prostate and penis. About 3 cm long, the 
prostatic urethra hugs anterior portion of prostate gland and is divided into proximal and distal 
segments by an abrupt anterior angulation of 30º in its mid portion. Distal to the urethral 
angulation it has a midline longitudinal ridge in its posterior wall, the Verumontanum.(1, 2) 
Located superior to the base of the prostate, the seminal vesicles undergo confluence with the 
vas deferens on each side to form the ejaculatory ducts – see Figure 2. The ejaculatory duct 
complex consists of the two ejaculatory ducts along with a second loose stroma rich in vascular 
spaces. The two ejaculatory ducts open in distal urethral segment that also receives about 95% of 
the ducts of glandular prostate. When present, the utricle is located between the ejaculatory 
ducts and its remnants occasionally form cystic structures in the midline posteriorly. Seminal 
vesicle involvement (SVI) by prostate cancer (PCa) is one of the most important predictors for PCa 
progression.(1, 3, 4) – see Figure 2. 
The term “capsule” is used in the current literature, but there is no consensus about the presence 
of a true capsule in the prostate. This prostatic “capsule” is composed of fibrous tissue 
surrounding the gland and is best appreciated posteriorly and posterolaterally, between the 
prostatic stroma and extraprostatic fat (2). 
The prostatic branches of the inferior vesical artery are the main arterial supply to the prostate 
gland. It is also supplied by small branches from the middle rectal and pudendal vessels. The veins 
are situated mainly in the prostatic “capsule” and the lymphatic vessels from the prostate drain 
into internal iliac lymph nodes. 
Being the largest accessory reproductive gland in man, the prostate contracts with the ejaculation 
and has as primary function to provide enzymes to maintain the fluid nature of seminal fluid and 
to nourish sperm.(2, 4) – see Figures 1 and 2. 
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Figure 1 Median sagittal section of the male pelvis. Adapted from (5) 
 
Figure 2 Illustration of the prostate gland localization. Adapted from (6) 
 
1.2. Zonal Anatomy and Histology of the Normal Prostate 
McNeal JE introduce the concept that the prostate gland was composed of diverse zones rather 
than lobes and established the current and most widely accepted division of the prostate gland 
into four basic anatomic zones, on the basis of biological and histological concepts, the peripheral 
zone (PZ), the central zone (CZ), the transitional zone (TZ) and the anterior fibromuscular stroma 
(AFMS/AFS). (2, 7, 8) – see Figure 3.  
The peripheral zone constitutes about 70% of the glandular part of the prostate, comprising all 
the glandular tissue at the apex and all of the tissue located posteriorly near the capsule. Its ducts 
open into prostatic urethra distal to verumontanum. The glands of the peripheral zone have 
rounded contours and its stroma is loosely woven with randomly arranged smooth muscle. 
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Diseases of the prostate, such as carcinoma, chronic prostatitis and postinflammatory atrophy, 
are more common in this zone than in the others. (1, 2, 7, 9) 
The central zone is cone-shaped and comprises 25% of the glandular prostate. The apex of the 
cone is at the confluence of the ejaculatory ducts and the prostatic urethra at the verumontanum. 
This zone is surrounded by the peripheral zone in its distal part, surrounds the ejaculatory ducts 
and is relatively resistant to carcinoma and other diseases. Central zone glands are larger, more 
complex and often located in lobules around central ducts, ridges and arches. The stroma in this 
zone is less abundant but contains compact smooth muscle fibres. Biochemically, the CZ is the 
only zone which produces pepsinogen II and tissue plasminogen activator. (1, 2, 9) 
The transitional zone consists of two equal and independent lobes of glandular tissue. Its ducts 
open in the postrolateral part of urethra. The glands of this zone have rounded contours and its 
stroma contains more compact, interlacing smooth muscle bundles. This zone is clinically 
important as it is involved in the development of age-related benign prostatic hyperplasia (BPH). 
(2, 9) 
The anterior fibromuscular stroma forms the convexity of the anterior external surface and 
consists of a band of fibromuscular tissue contiguous with the bladder muscle and the external 
sphincter. Its distal portion is important in voluntary sphincter functions and its proximal portion 
in involuntary sphincter functions.(1, 2, 9) 
Zonal anatomy has replaced lobar anatomy with one exception. The term “median lobe” was 
originally designated as a third lobe occasionally palpable on digital examination above and 
between the two lateral lobes. It can be visualized on cystoscopy as a posterior encroachment, as 
opposed to lateral encroachment from TZ hypertrophy and it is visible on ultrasound, magnetic 
resonance imaging (MRI) and Computed tomography (CT) as a distinct form of hypertrophy with a 
large intralumen component. The median lobe has a unique behaviour and its presence has 
implications to radiation treatment planning and treatment selection.(9) 
 
Histologically, two cells layers can be found in the prostate gland. A luminal secretory columnar 
cell layer line the entire tubulo-alveolar organisation of the prostate, with the exception of the 
main lateral ejaculatory ducts that are lined by transitional cell epithelium just before they enter 
the urethra.(2) The typical gland is lined by a basement membrane (BM) composed of type IV 
collagen, fibronectin, laminin, heparin sulphate and entactin. An underlying basal cell layer 
separates the columnar secretory cells from the BM. The basal cells have little discernible 
cytoplasm and darkly stained nuclei. The function of these basal cells is poorly understood, but 
they are histologically important as their presence differentiates between benign disease and 
adenocarcinoma when they are not present. The secretory cells (epithelium) secrete proteins 
such as prostate specific antigen (PSA) and prostatic acid phosphatase (PAP) into the seminal 
plasma. The glands secrete mucins and produce lipofuscin. They also secrete citric acid and acid 
phosphatase.(2, 10) 
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Figure 3 Prostate illustrations of McNeal’s zonal anatomy. Adapted from (6) 
 
1.3. Neural Anatomy of the Normal Prostate 
The prostate gland is an extraordinarily well-innervated organ that receives dual autonomic 
innervation, both parasympathetic and sympathetic. The cholinergic innervation is from the 
hypogastric and pelvic nerves and the noradrenergic innervation from a peripheral hypogastric 
ganglion. Two neurovascular bundles are located posterolaterally adjacent to the gland and form 
the superior and inferior pedicles on each side. (2) – see Figure 4. 
Both autonomic fibres innervate the prostate stroma. Cholinergic nerves innervate the smooth 
muscle of the capsule and the space around the blood vessels, being responsible for the secretory 
function of the epithelial part. Sympathetic nerves control the prostatic musculature and their 
excitation closes the bladder neck during ejaculation of the seminal fluid into the urethra. There is 
an increasing interest on nerve-sparing surgical treatment of PCa, because of the demonstrated 
importance of these nerves in penile erection. (2) 
 
 
Figure 4 Illustration of the prostate gland, showing the zonal anatomy and the neuro-vascular anatomy. Abbreviations: 
AFS, anterior fibromuscular stroma; TZ, transitional zone; U, Urethra;  CZ, central zone; ED, ejaculatory duct; PZ, peripheral zone. 
Adapted from (6) 
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1.4. Relevance of Prostate Zonal Anatomy and Histology in Clinical Practice 
A sound knowledge and application of prostate gland histology and anatomy is required for the 
diagnosis of different pathological conditions including benign prostatic hypertrophy (BPH) and 
allow a more scientifically based selection of medical therapy for men with prostate disease.  
A key landmark for endoscopic procedures of the lower urinary tract is the verumontanum. To 
avoid damage to the external urethral sphincter and preserve continence, when an endoscopic 
surgery such as transrectal ultrasonography (TRUS) of the prostate or bladder neck incision (BNI) 
is performed to relieve bladder outflow obstruction, resection is not pursued distal to the 
verumontanum. The obturator nodes are usually the first to be involved in metastatic spread. So, 
during radical prostatectomy, the obturator nodes or other pelvic lymph nodes can be sampled to 
provide useful tumour staging information. (11) 
The origin of the tumours can be established according to the sample technique used. When a 
transrectal ultrasound guided core biopsy is performed, the regions of the prostate sampled are 
likely to consist of tissue from the peripheral zone, seldom the central or transitional zones. When 
a TRUS is performed, the specimens will mostly consist of tissue from the urethra, bladder neck, 
periurethral zone, transitional zone and anterior fibromuscular stroma.(8) On one hand, a well 
differentiated carcinoma found in TRUS specimens is more likely to represent carcinoma 
originating in the transitional zone. On the other hand, a poorly differentiated carcinoma in TRUS 
specimens may represent tumour originating in the peripheral zone that invades the transitional 
zone.(11) 
 
Based upon the concept of a prostate gland divided into four basic anatomic zones, it has been 
possible to establish the different neoplastic potential of the zones and the effect of the zonal 
origin on prognosis.  
The predominant thought was that PCa arose nearly exclusively in the posterior part of the 
prostate (peripheral zone) close to the prostatic capsule. But more recent studies confirmed that 
in prostates removed for PCa a significant minority of PCa foci arise in the transition zone and 
central zone.(2) Has been also described the unique well-differentiated nature of tumors arising in 
the transition zone (Gleason pattern 1 and 2), which are characterized with a low risk of 
progression and being rarely associated with capsular invasion or seminal vesicle involvement 
(SVI). (2) 
It is also known that the parenchymal components of the prostate vary in the size, shape and the 
number of acini in different zones. So, the greater number of acini in PZ can explained the higher 
incidence of adenocarcinoma in this zone. The loosely woven stroma in PZ and compact stroma in 
TZ can also explained the occurrence of adenocarcinoma from the acini of PZ and the BPH in 
TZ.(2, 7) 
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2. Prostate Cancer 
2.1. Epidemiology 
2.1.1. International Prostate Cancer Epidemiology 
Being the second most frequently diagnosed cancer of men and the fifth most common cancer 
overall, there are 899 000 new cases of prostate cancer every year (13.6% of the total) and nearly 
three-quarters of the registered cases occur in developed countries (644 000 cases). (12) 
Prostate cancer is the sixth leading cause of death from cancer in men (6.1% of the total), with an 
estimated 258 000 deaths in 2008 and the second leading cause of cancer-related death of men in 
the United States. Incidence rates of prostate cancer vary by more than 25-fold worldwide. 
Australia/New Zealand, Western and Northern Europe, Northern America have the highest rates 
because of the widespread practice of prostate specific antigen (PSA) testing and subsequent 
biopsy in those regions. Certain developing regions (Caribbean, South America and sub-Saharan 
Africa) have incidence rates relatively high, while South-Central Asia has the lowest age-
standardised incidence rate (4.1 per 100,000). (13) 
Adenocarcinoma, which accounts for about 95% of prostatic neoplasms, has frequently no 
specific presenting symptoms. Prostate cancer (PCa) is often clinically silent and sometimes 
mimics obstructive symptoms of Benign Prostate Hyperplasia (BPH). Consequently, has come to 
the forefront of focus the diagnostic value of patient screening by using early detection programs 
like the widespread screening with serum prostate specific antigen (PSA). PSA testing has a much 
greater effect on incidence than on mortality. With the introduction of this test, the incidence of 
stage IV PCa at presentation has dramatically lessened, although the number of PCa detected has 
increased as well. There is less variation in mortality rates worldwide than is observed for 
incidence, and the number of deaths from PCa is almost the same in developed and developing 
regions. Mortality rates are generally high in predominantly black populations (Caribbean, sub-
Saharan Africa), very low in Asia and intermediate in Europe and Oceania. (14) 
 
2.1.2. Portuguese Prostate Cancer Epidemiology  
Prostate cancer is the second most common cancer among Portuguese men in 2000 (2973 new 
cases). There is a cumulative risk (0–74 years) of 3.2 % of a Portuguese individual developing 
prostate cancer and a total cumulative risk of 3.0 % of dying from prostate cancer.(15) 
During the period of 1988 to 1998 the overall age-standardised cancer mortality rate for men in 
Portugal increased (1.4 % annually), with prostate cancer (3.6 % annually) mostly contributing. In 
the middle of 1990s the level of prostate cancer mortality in Portugal was similar to the EU 
average and approximately 35 % higher than in Southern European countries. However, in the 
years 1978 to 1994, the increase in prostate cancer mortality in Portugal and other Southern 
European countries such as Italy and Spain was lower than in most Northern European countries, 
and similar to those of Western Europe such as France, Austria and Germany. As mentioned 
before, the introduction of some prostate-screening programmes, based on PSA testing, may be 
the cause of the gradual reduction in mortality (due to an earlier diagnosis) in some countries of 
Europe (Austria, France, Germany, Italy), where the decreasing in mortality trends in the age 
group 50–79 years began in the 1990s. (15) 
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2.2. Aetiology of Prostate Cancer 
The currently established risk factors for prostate cancer are increasing age, family history and 
ethnicity. 
Age is the most significant risk factor of all for prostate cancer. More than half of all cases of PCa 
are diagnosed in men over 70 and it is quite rare in men under 50. In old age, up to 8 out of 10 
men have prostate cancer cells in the prostate.(16, 17) 
Family history is also an important risk factor for PCa. If you have a father or brother diagnosed 
with prostate cancer you are 2 to 3 times more likely to get prostate cancer yourself, compared to 
the average man. And with more than one first degree relative diagnosed, your risk is about 4 
times that of the general population.(17, 18) Also an important factor is the age that your relative 
is diagnosed with prostate cancer. The younger they were diagnosed (before the age of 60), the 
higher your risk for developing PCa. A case of an inherited faulty gene can be the cause of having 
several relatives with prostate cancer, especially if they were diagnosed when they were young. 
For example, men who have relatives with breast cancer may have a higher risk of prostate 
cancer, mainly caused by an inherited faulty gene called BRCA2. Men who have a mutation in the 
BRCA2 gene can have a risk 5 times higher than men in the general population and this risk 
increase (7 times) in men under the age of 65.(18) 
As mentioned before, ethnicity also influences the risk for prostate cancer. PCa is more common 
in black populations than in white or Asian men, being the black African and black Caribbean men 
2 or 3 times more likely to develop prostate cancer than white men. Asian men have a lower risk 
than white men. A mixture of inherited genes and environmental factors seem to be the cause of 
these differences. When men move from a country where the prostate cancer risk is low to one 
where it is higher their risk increases.(19) 
There is a keen interest in establishing potentially modifiable factors, such as diet, lifestyle, 
endogenous hormones and medical conditions/interventions, but no definitive evidence to 
support a change in treatment strategy currently exists. For example, many studies have looked at 
dietary factors and prostate cancer risk. This type of research is difficult and much of the research 
has not found any definite links between particular foods and the risk of prostate cancer. 
Recently, though, has been found that foods containing lycopene and selenium probably reduce 
the risk of prostate cancer.(20, 21) Lycopene is found mainly in tomatoes and tomato based foods 
and selenium is a naturally occurring chemical found in plant foods, fish, shellfish, some meats, 
grains, eggs, Brewer's yeast, and wheat germ. Diets high in calcium and dairy protein may increase 
the risk of prostate cancer.(21) Hormone levels may or may not play a part in the risk of 
developing prostate cancer. The prostate gland is a sex organ that needs the sex hormone 
testosterone to work. In the past, it was thought that having higher levels of testosterone in the 
blood may increase the risk of prostate cancer. But, in 2008 an analysis of 18 separate studies 
found no link between levels of sex hormones and prostate cancer risk.(22) 
 
2.3. Androgen Receptor Pathway in Prostate Cancer 
Androgens serve as a most important ligand for prostate cancer (PCa), stimulating growth via the 
androgen receptor action pathway. The androgen receptor action pathway includes the androgen 
receptor, the 5-alpha-reductase gene and the various members of the cytochrome p450 
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family.(23) About 10 to 20% of PCa specimens have mutations within the AR gene, with mutations 
more common in hormone escape than hormone sensitive specimens. The androgen receptor 
(AR) has three important domains: N-terminal transactivation domain, DNA binding domain and 
C-terminal steroid binding domain.(23, 24) 
Several studies have already shown that the action of AR in prostate development is mediated by 
the local stroma. Also, it has been shown that oestrogens have a role in cancer development, yet 
the oestrogen receptor is predominantly localized in stromal cells. . Animal models have 
demonstrated prostatic cell proliferation occurs in androgen deficient mice due to exogenous 
oestrogen. In addition, elevated androgen levels in oestrogen deficient mice induced prostatic 
hyperplasia. Therefore, neither of these hormones alone induced prostate cancer, but combined 
androgen and oestrogen therapy did evoke prostatic dysplasia and adenocarcinoma. Thus, both 
androgens and oestrogens influence the process of prostate carcinogenesis.(25-27) 
The androgen deprivation therapy (ADT) is used to prevent activation of AR regulated genes. And 
the failure of ADT, as in hormonally resistant prostate cancer, was linked to genetic modification 
of the AR.(26) More recently, the effect of post-translational modifications on the AR has been 
recognized. The phosphorylation of the AR in response to binding by the ligand DHT 
(dihydrotestosterone) has been demonstrated. This phosphorylation can stabilize the active AR 
homodimers and also influence AR mediated gene activation.(28) In addition, the phosphorylation 
of AR by MAPK (serine-threonine kinase) and AKT (protein kinase B) sensitizes AR to low levels of 
DHT, which allow low levels of androgens, or alternative steroids, to induce translocation of the 
AR to the nucleus, facilitating gene activation. MAPK has been shown to be activated in cell lines 
derived from hormone-refractory tumors and is correlated with advanced stage and grade in PCa. 
AKT can be activated via PI3 kinase pathway and specifically phosphorylates AR at Ser210 and 
Ser790 (25, 27-29) – see Figure 5. 
It is also important to notice that the control of AR function also involves interaction of the 
receptor with a number of co-factors or proteins that increase (co-activators) or inhibit (co 
repressors) the transcriptional activity of the AR. Co-activators include CBP (CREB-binding 
protein), beta-catenin, ARA55 and ARA70. They all act to alter ligand specificity of the AR and 
these mechanisms include allowing the antiandrogens such as hydroxyflutamide (CBP, ARA70) 
and bicalutamide (ARA70) to act as agonists and/or by permitting low concentrations of adrenal 
androgens or oestradial to activate AR. In addition, others co activators activate AR in the absence 
of ligands, such as SRC-1, SRC-3, p300, Tip60, and c Jun. Lastly, there is a less well understood 
mechanism of AR co-activators which involves movement of AR to the nucleus. It is via this 
mechanism that the STAT3/AR complex activates AR-dependent genes (in the absence of 
androgens) in response to IL-6 stimulation.(25, 30) 
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Figure 5 Illustration of the Androgen-receptor signalling in prostate cancer. The left panel illustrates the hormone-
dependent androgen signaling that takes place through dihydrotestosterone stimulation of the androgen receptor; The 
right panel illustrates the hormone-refractory prostate cancer cells that survive through stimulation of multiple 
signaling pathways, including the PI3K and the MAPK pathways, which culminate in androgen-receptor signaling, or 
alternate pathways that lead to cell proliferation, migration and survival.  
Abbreviations: AKT, protein kinase B; AR, androgen receptor; ARE, androgen response element; DHT, dihydrotestosterone; GF, growth 
factor; IGF1, insulin-like growth factor 1; IL-6, interleukin 6; JAK, Janus kinase; MAPK, mitogen-activated protein kinase; MEK, upstream 
kinases of mitogen-activated protein kinases, also known as MAP2Ks; P13K, phosphatidylinositol 3 kinase; mRNA, messenger RNA; 
STAT3, signal transducer and activator of transcription 3; TK, tyrosine kinase. Adapted from (31) 
 
2.4. The Gleason Grading System 
Currently, the strongest prognostic factor of a patient’s time to progression is the Gleason grading 
system, being the ‘gold standard’ for classifying prostate cancer (PCa).(32) The histologic analysis 
of PCa based on the Gleason system describes the histologic appearance of PCa under low 
magnification. It assigned a rating between 1 and 5 to the tumour, based on architectural 
patterns, with higher numbers representing less differentiated, more aggressive tumours. Well-
differentiated PCa (Gleason grade 1 or 2) is characterized by a proliferation of microacinar 
structures lined by prostatic luminal cells without an accompanying basal cell layer. Some of the 
neoplastic cells contain prominent nucleoli, defined as at least 1 μm in diameter. Gleason pattern 
5 is the highest grade and includes a solid pattern with central necrosis or infiltrating individual 
cells – see Table 1.(2, 32)  
A single prostate can harbour multiple foci of different histologic patterns of adenocarcinoma, 
and it is possible to have two or more grades in the same specimen (85% of prostate tumours are 
multifocal). The Gleason score (or Gleason sum) incorporate both a primary (dominant) and a 
secondary (subdominant) grade into the system. The primary pattern is added to the secondary 
grade to arrive at a Gleason score, i.e.: in a tumour with mostly Gleason grade 3 and some 
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Gleason grade 4 disease, the Gleason score will be 3+4=7. Consequently, the Gleason score 
possibilities range from 2 (1 + 1) up to 10 (5 + 5), assessed by the uropathologist using low-power 
light microscopy.(2, 33)  
There are several limitations concerning Gleason system as a grading system. First, Gleason 
grading is observer dependent and may vary depending on the level of experience. Second, the 
majority of patients diagnosed today fall into the Gleason 6–7 category, an intermediate 
prognostic range limiting the potential usefulness of a 10-point scale. (2) 
 
Grade Histology Biological Behaviour 
1, 2 Closely-packed glands forming a 
nodule 
Indolent disease, rarely 
progressive 
3 Small infiltrating glands, 
complete lumen formation 
Most common pattern; less 
aggressive than pattern 4 
4 Fused glands, incomplete lumen 
formation 
Indicates tumour progression 
5 Solid sheet or single cells, no 
lumen formation 
Very aggressive, late stage 
Table 1 Gleason grading system. Adapted from (32) 
2.5. Limitations of Conventional Histopathology 
Pathology is the gold standard for prostate cancer diagnosis and obtaining prostate tissue 
specimens with the disease present is necessary for prostate cancer diagnosis. However, as 
mentioned before, prostate cancers are often multifocal and heterogeneous in pathology. So, 
prostate core biopsies may contain limited carcinoma within the sample and cancer diagnoses can 
be missed on account of human error. This fact means that negative biopsies do not exclude the 
possibility of prostate cancer, likewise that positive biopsies may not contain or reflect the degree 
and severity of prostate cancer present. In a case of a positive biopsy for PCa, there is also an 
inter-observer variation in applying Gleason grade, being the variability in interpretation the main 
problem.(33, 34) Recognise the border areas between Gleason patterns and that microscopic foci 
of carcinoma do not necessarily represent low grade carcinoma are important difficulties faced by 
the uropathologists. Some improvements in Gleason grading have been achieved by online 
tutorials and regular refresher courses. However, the subjectivity in interpretation of the Gleason 
grade continuous to be a concern because of the pathological assessment guides treatment.(35-
37) 
 
3. Diagnostic modalities of Prostate Cancer 
3.1. Clinical Signs and Symptoms 
Early localized prostate cancer is often asymptomatic. However, PCa may cause prostate gland 
enlargement, which leads men to present a number of unique symptoms, related to the 
prostate’s location in the body. As the prostate enlarges, the prostatic urethra is pinched tighter 
and tighter within the prostate. As the tube narrows, urine has a much harder time making its way 
through the urethra and out of the body. This results in four primary urinary symptoms: 
Frequency, that is the need to urinate much more often than normal; Urgency, that is the 
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sensation that you need to urinate immediately; Nocturia, that is the need to urinate multiple 
times during the night; and Hesitancy, that is the difficulty to start the urine stream. (38-40) 
It is important to realize that PCa is not the only disease that can cause the prostate to swell and, 
consequently, these urinary symptoms. A much more common cause of an enlarged prostate is 
Benign Prostatic Hyperplasia (BPH). (40) Also, the majority of prostate cancers arise in the 
peripheral zone; however, it is unusual that sufficient enlargement will occur in the PZ to cause 
urinary symptoms. Transitional zone tumours and large PZ tumours may cause urinary outflow 
symptoms, but it is the coexistence of transitional zone enlargement secondary to hyperplasia 
that may contributes to most men presenting these symptoms. (40-42) 
Cancer of the prostate gland often grows slowly, especially in older men and symptoms may be 
mild and occur over many years. If the prostate cancer is advanced, other less common symptoms 
may develop, which are less specific to problems with the prostate (problems with other organs 
such as the bladder can also cause them). These include blood in the urine (Hematuria), blood in 
the semen (Haematospermia), perineal discomfort and new-onset erectile dysfunction 
(Impotence). Advanced prostate cancer commonly spreads to the bones, and cancers cells in the 
bone may cause pain in the hips, back (spine), ribs (chest), or other areas. A cancer that has 
spread to other areas of the body is called metastatic or secondary prostate cancer. If the cancer 
spreads to the bones of the spine, it will usually press on the spinal cord or its nerves, leading to 
weakness or numbness in the legs or feet and even loss of bladder or bowel control.(40-42) 
3.2. Digital Rectal Examinations 
Palpation of the prostate by digital rectal examination (DRE) allows assess the external contour of 
the prostate gland. (43) By itself, DRE is a poor method for diagnosing PCa, as it is not specific for 
cancer, both prostatitis and benign prostatic hypertrophy (BHP) may cause an abnormal 
examination.(43, 44) However, up to 50% of palpable masses are attributable to prostate cancer 
and can be detected by DRE, especially cases of prostate cancer with a palpable volume of 0.2 ml 
or more and originating in the peripheral zone (PZ).(41, 45) It is also particularly important the 
detection of a palpable mass/nodule at the prostatic apex. Its presence is often indicative of 
extraprostatic extension at that location and tends to foreshadow a positive surgical margin or 
poorer result post-radiotherapy. (46, 47) 
Unfortunately, when a PCa is diagnosed based on a palpable tumour, there is a high risk of the 
patient already harbours metastatic or locally advanced malignancy. That is why the risk of a 
positive DRE turning out to be a prostate cancer should be evaluated together with the results of 
the PSA value: the higher the PSA value the more likely the DRE assessment will be positive. DRE 
still have an important diagnostic role, as 30% of tumours are detected by abnormal DRE in men 
with normal PSA levels, < 4.0ng/ml. DRE is also important for the clinical staging of the 
disease.(48, 49) 
 
3.3. Prostate Specific Antigen  
Prostate specific antigen (PSA) is a kallikrein-like serine protease produced almost exclusively by 
the epithelial cells of the prostate and secreted into the ductal system. In serum, it is normally in 
complex with α-1-anti-chymotrypsin and α-2-macroglobulin, only a small percentage of serum 
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PSA is in its free form. Serum PSA is determined by immunoassay techniques and monoclonal 
antibodies have been designed to detect the free form of PSA, the complex of PSA and α-1-anti-
chymotrypsin and the total PSA.(50-52) 
Prostate specific antigen (PSA) was discovered in 1979 by Wang et al and since then PSA testing 
has revolutionized the detection of prostate cancer and monitoring of its treatment.(52, 53) The 
PSA testing was initially approved by the FDA in 1986 for monitoring the disease status of prostate 
cancer patients and in 1994 it was endorsed as a screening method for PCa. Although many 
studies demonstrate benefits for PSA screening in reducing mortality, the benefits for screening in 
improving survival are yet to be proven.(54, 55) 
The PSA screening has many strengths, as it can precede the appearance of a palpable mass by as 
many as ten years, tumour-induced symptoms by 5-10 years and, on average, death by prostate 
cancer by 17 years. However, it is important to notice that PSA is not a test for prostate cancer 
and an abnormal serum PSA only indicates that something is likely to be awry in the prostate that 
includes cancer as one possibility.(56-58) It is also important to recognize that there are non-
malignant causes that can produce an elevated PSA (>4.0ng/ml): these include infection, benign 
prostatic hyperplasia (BPH), ageing endorsing age-based reference ranges and instrumentation of 
the prostate and urinary tract.(59-61) Also certain drugs, such as finasteride, can lower PSA values 
by approximately 50%. (62) 
There is no universally accepted cut off point or upper limit of a normal PSA. Values over an 
arbitrary cut off point of 4.0ng/ml are inferred to be abnormal; however, many men may harbour 
prostate cancer with a low serum PSA. The Table 2 shows the risk of prostate cancer in relation to 
low serum PSA values. In the large majority of cases of PCa an elevated serum PSA levels, mostly 
between 4.0-10.0 ng/ml, are present.(63) In these cases, usually the next step in elucidating the 
cause of an elevated PSA is a prostatic biopsy. However, most men undergoing prostatic biopsies 
have negative histology for cancer, even when more than 8 TRUS-guided biopsies are taken, with 
biopsies repeated if suspicion of an undetected malignancy is high.(64, 65) A serum “cut-off” of 
3.0ng/ml has been advocated to increase the likelihood of detecting PCa. However, it has been 
reported that approximately 15% of PCas detected by investigating a serum PSA level between 
3.0-4.0 ng/ml had extraprostatic growth and with this PSA threshold of 3.0ng/ml, the negative 
biopsy rate has increased. (48, 66-69) 
Improving the characteristics modifications of the PSA has been considered and there are 
different tests that can be performed in a PSA screening: the free/total PSA, the PSA velocity and 
the PSA density.(51, 70) The first one, the free/total PSA (f/t PSA), measures the percentage of 
free/unbound PSA in the blood, and compares it with the percentage bound to proteins, with its 
application most useful in younger men. As in PCa most of the PSA in blood is bound, the lower 
the ration of free to total PSA or the percentage of free PSA, the higher the likelihood that the 
patient has PCa. The free/total PSA test can help to discriminate between patients with 
indeterminate PSA levels (4.0-10.0 ng/ml) who are at the greatest risk of having prostate cancer, 
in particular aggressive disease.(70-72) The PSA velocity measures the speed at which a series of 
PSA values increases in value over a period of time and any change in PSA >0.75 ng/ml in a year is 
concerning for PCa.(73) The PSA density (PSDA) measures the concentration of PSA in a man’s 
prostate by comparing the value of his PSA and the size of his prostate. As most neoplastic 
prostate glands produce higher serum PSA levels than do non-malignant glands, a serum PSA of 
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5.0ng/ml in a patient with a 20 gram prostate is more worrisome for cancer than that a PSA of 
5.0ng/ml in a patient with a 60 gram prostate. In order to determinate the PSA density, a PSA 
level is obtained and is divided by the volume of the prostate, estimated by transrectal 
ultrasonography (TRUS). A value >0.15 ng/ml per gram of prostate tissue concerning for PCa. As 
the transition zone (TZ) is the site in which BPH develops and about 25% of PCas also arise in this 
zone, it is also important to include TZ measurements in relation to the overall size of the 
prostate. Therefore, the larger the TZ in relation to the overall size of the gland, the lower the 
likelihood of prostate cancer, other things being equal.(74-76)  
 
PSA level (ng/ml) Risk of Prostate Cancer (%) 
0-0.5 6.6 
0.6-1 10.1 
1.1-2 17 
2.1-3 23.9 
3.1-4 26.9 
Table 2 Risk of prostate cancer in relation to low serum PSA values. Adapted from (77) 
3.4. Molecular Markers (Biomarkers) for Prostate Cancer Detection 
Prostate cancer (PCa) is a phenotypically heterogeneous disease and alterations in cancer cells 
occur at many levels, both pre and post transcriptionally (in the genome and transcribed RNA), 
and post translational protein modifications. So, there is an increasing interest in establish reliable 
prostate cancer biomarkers to identify cancer cells in blood, bone marrow, urine, prostatic tissue 
and semen. A biomarker is a biological molecule that can be found in both body fluids or tissues 
and that is a sign of a normal or abnormal process or of a condition or disease. It can also be used 
to see how well the body responds to a treatment for a disease or condition.  
It has been noted that the genes, their transcription rates and subsequent proteins altered in 
prostate cancer can be grouped into a number of cellular pathways: cell adhesion, cell-cycle 
regulation, cell signalling, angiogenesis and apoptosis. The main molecular aberrations in prostate 
cancer are summarized in Table 3. 
 
Cellular pathway Molecular markers Process 
Cell Adhesion 
E-cadherin, 
metalloproteinases, 
kallikreins, CD151 
The aberrant expression of cell-cell adhesion molecules (C-
CAMs), including E-cadherin, is associated with the 
development of tumors and the decreasing of its expression 
have been associated with the progression of PCa  and several 
other types of neoplasm.(78) 
CD44 is also a cell adhesion molecule that has been associated 
with prostate cancer. However, the molecular based profiling 
may depend more on overexpressed molecules and the activity 
of MMP’s 2 and 9, uPA and uPAR, and KLK2, 3 (PSA) and 4 in 
interfering with cell adhesion may be more relevant. The 
efficacy of both KLK2 mRNA and its protein product, hK2, as 
stand-alone biomarkers or in combinations with other known 
biomarkers (PSA), has been studied.(79-81) Both KLK4 and its 
protein product, hK4, have also been associated with prostate 
cancer. KLK4 expression is regulated by androgens, oestrogen 
and progesterone in prostate cancer cells and seems to be 
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overexpressed in prostate cancer. (82) 
CD151 is a cell adhesion associated molecule plays a role as a 
link between extracellular matrix and intracellular structures 
and may be relevant prognostically as the increase of its protein 
levels in well and moderately differentiated prostate cancers is 
correlated with disease relapse subsequent to radical 
prostatectomy. (83) 
Cell-cycle 
regulation 
Cyclin family, RBp, 
p16, p21, p27, p53, 
Smad4, FHIT, and 
PTEN/MMAC1 
Cyclin family, RBp (retinoblastoma protein), p16, p21, p27, p53, 
Smad4, FHIT, and PTEN/MMAC1 are some of the molecules 
involved in the control of progression in the cell cycle that have 
its expression altered in PCa.(78) Poor prognostic outcomes are 
related with increased expression of p16 and p21. Also some 
prognostic value is given to the loss of RBp and p27. (78, 84) 
In clinically localized PCa, the strong expression of a catalytic 
subunit of the polycomb repressor complex 2, EZH2, is 
associated with poor prognostic. In hormone refractory PCas its 
overexpression is also observed.(85) The E2F3 transcription 
factor is responsible for EZH2 regulation and its shown nuclear 
expression in 20% or more of prostate epithelial cells may also 
be an indicator of an unfavourable clinical outcome.(86) 
Cell Signalling 
TGF-beta, EGF, IGF 
Caveolins 
Cell-cell signalling is mediated by a number of soluble and 
insoluble proteins and factors, including growth factors (TGF-
beta, EGF and IGF) and cytokines (Il-6).(87) 
Caveolins are major structural proteins of the Caveolae1. 
Caveolin-1 is an important caveolin, demonstrated to be 
implicated in oncogenic cell transformation and subsequent 
metastasis. In PCa, caveolin-1 seems to function as a tumour 
promoter, via both genetic and post-translational 
modifications.(88) 
c-Myc and caveolin-1 immunopositivity are correlated 
positively with Gleason score (P = 0.0253) and positive surgical 
margin (P = 0.0006). So, the combination of positive c-Myc and 
caveolin-1 in patients with clinically confined PCa may be a 
significant prognostic marker for disease progression after 
surgery.(89) 
Angiogenesis 
VEGF, VEGF 
receptors, PSMA 
VEGF is a key component in angiogenesis and has prognostic 
value, since it is highly expressed in most PCas. It has been used 
as target for therapeutics, which has been demonstrated to be 
a very important targeting pathway, since hypoxia is a known 
important factor that induces VEGF production.(90, 91) 
PSMA (prostate-specific membrane antigen) is expressed by 
both tumour epithelium and tumour associated endothelial 
cells and neovasculature.(92) PSMA has also been used as a 
target for therapeutics, being made a series of antibodies 
against the external domain of this protein.(93, 94) Some 
studies proposed that PSMA may function as a ligand 
internalizing receptor, an enzyme playing a role in nutrient 
uptake, and a peptidase involved in signal transduction in 
prostate epithelial cells.(95-97) So, a specific PSMA transcript 
may have applicability as a biomarker for PCa, particularly when 
used in combination with other gene transcripts, such as 
                                                        
1 Specialized plasma membrane invaginations that are abundant in smooth muscle cells, adipocytes and 
endothelium, and act as regulators of signal transduction. 
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DD3/PCA3. (95, 98) 
Apoptosis p53, Bcl-2, Clusterin 
Some key regulators of apoptosis, which can be pro-apoptotic 
(p53) or anti-apoptotic (Blc-2), show abnormal function and 
expression in cancer cells. 
p53 regulates transcription of genes important for G1-phase 
growth arrest of cells in response to DNA damage and 
mutations in p53 are a common event in early stage, organ-
confined PCa.(99) Its use as a diagnostic marker is controversial 
due to the heterogeneity of expression within tumours. Since 
metastatic, recurrent and androgen resistant cancers show 
higher number of cells with p53 immunoreactivity compared 
with primary tumours, this pro-apoptotic protein has great 
potential as a prognostic marker.(78, 100) 
The value of Bcl-2 as a diagnostic marker is unclear, since some 
groups have shown that only limited numbers of prostatic 
tumours express Bcl-2.(101, 102) However, some studies have 
demonstrated correlation with Bcl-2 and poor prognostic 
outcomes, with increased numbers of high-grade and 
metastatic tumours having Bcl-2 immunoreactivity.(103, 104) 
Bcl-2 overexpression in tumours has also been associated with 
resistance to radiotherapy. (105) 
TRPM-2 (testosterone-repressed prostate message-2) or 
clusterin or sulfated glycoprotein-2. An increased expression of 
TRPM-2/clusterin protein is evident in PCa (96%) compared 
with BPH (73%) and normal prostate epithelium (17%).(106, 
107) TRPM-2/clusterin has a well-documented anti-apoptotic 
function.(108) However, it seems to have many functions, some 
of them with pro-survival effects. (109) 
Others 
Hepsin, PSCA, non-
coding RNA’s 
DD3/PCA3 
Hepsin is a type II transmembrane serine protease that is 
differentially expressed in PCa compared with normal and BPH 
affected prostate tissue.(110) Some in-vitro studies had 
demonstrated that Hepsin overexpression had growth 
inhibitory effects.(111) It has also been found a model for 
Hepsin and tumour progression when the soluble form of 
Hepsin was found to activate HGF (hepatocyte Growth 
Factor).(112) Therefore, there is an increasing interest in the 
development of antagonists to Hepsin and subsequently HGF 
activation, which could be useful therapeutically. (112, 113) 
Prostate stem cell antigen (PSCA) is a prostate specific 
glycoprotein that is expressed by PCa cells as a cell surface 
antigen and is regulated by the androgen receptor.(114-116) It 
has a central role in the development of the prostate gland and 
could provide a new diagnostic and therapeutic target for PCa, 
as its increase expression has been related to an increased PCa 
risk. (115, 117) 
DD3/PCA3 was identified by differential display technology in 
1999 as a non-coding RNA highly specific to PCa. Since then, the 
Prostate Cancer Gene 3 (PCA3) has been used in clinical 
practice albeit only in certain institutions in the United 
Kingdom. It is present in urine and expressed in prostatic 
secretions, semen and prostate tissue.(118, 119) This 
biomarker is usually measured in urine after DRE and prostatic 
massage which allows shedding of prostate epithelial cells and 
is evaluated using reverse transcriptase polymerase chain 
18 
 
reaction (PCR).(119, 120) In 95% of prostate cancers PCA3 is 
over expressed, with studies to date showing sensitivity and 
specificity of 66% and 89% respectively. In patients with a PSA 
less than 4.0ng/ml, the sensitivity of PCA3 is increased.(118, 
121) However, there is a need for further refinement of this 
test before it would replace PSA in routine practice for 
screening. 
Table 3 The main molecular aberrations in prostate cancer. 
 
3.5. Transrectal Ultrasonography-guided Prostate Biopsies  
The second part of the contemporary two-step early-diagnostic approach for prostate cancer is 
the transrectal ultrasonography (TRUS)-guided prostate biopsy. It is usually performed after the 
possibility of a prostate cancer is raised, whether by rectal examination, PSA parameters, or a 
combination of both. The American Urologic Association established guidelines that recommend 
prostate needle biopsies for any man with a PSA value greater than 4.0ng/ml, or an abnormal 
prostate on DRE.(122) 
TRUS imaging allows spatial positioning of spring-loaded biopsy needles, providing a methodical 
approach for obtaining tissue cores for standard histopathology. TRUS imaging is usually non-
diagnostic by itself, but enables the operator to measure gland volume and delineate obvious 
focal lesions. When a standard sextant biopsy is performed, there is approximately 25% chance of 
missing a PCa.(123) Therefore, the number of biopsy cores taken is an important feature, being 
recommended at least 8 and preferably a minimum of 10 biopsy cores. Routinely, many urologists 
take 12 biopsy cores to minimize the likelihood of missing cancer. It is also advocated that 
biopsies should be directed laterally and that they should include the anterior horns of the 
peripheral zone.(124-126) Currently, indications for re-biopsy are rising in cases of a persistently 
high PSA, a suspicious DRE, or findings of Atypical small acinar proliferation (ASAP) or extensive 
Prostatic intraepithelial neoplasia (PIN).(127) 
Since TRUS biopsies are unpleasant and uncomfortable, many urologists routinely use anesthesia 
(local or general). The routine clinical practice also involves peri-operative antibiotic prophylaxis 
with a pre-procedural enema and not proceeding if any faeces at all are present in the rectum, as 
determined by DRE. This procedure has minor morbidity associated, with well over 50% of 
patients experiencing at least one complication. The dreaded complication of life-threatening 
sepsis is uncommon and blood in the urine, ejaculate and faeces are not infrequent sequelae with 
some men having difficulty voiding immediately following the procedure.(128-130) 
An accurate measurement of tumour volume based on biopsy findings is very difficult technically. 
However, it has been proposed that the biological aggressiveness of prostate cancer is a direct 
function of the tumour volume, which can implied that the larger the volume with biopsies, the 
greater the likelihood of extracapsular disease.(131-133) Therefore, the quantification of the 
amount of cancer on the needle biopsy, number of positive cores and core location give valuable 
information about individual tumour characteristics.(132, 134) 
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3.6. Suspicious results: Benign Prostatic Hyperplasia (BPH), Prostatic intraepithelial neoplasia 
(PIN), Atypical small acinar proliferation (ASAP) and Proliferative inflammatory atrophy 
(PIA) 
Sometimes the diagnosis of prostate cancer is difficult. The existence of signs and symptoms 
related to PCa or an elevated serum PSA levels do not necessarily indicate a case of prostate 
cancer, as there are other pathologies associated with these alterations. Even when a pathologist 
looks at the prostate cells under the microscope, they sometimes may not look cancerous but do 
not look normal either and these results are usually reported as suspicious. 
Benign prostatic hyperplasia (BPH) is a common pathological diagnosis that can only accurately be 
made after prostate tissue analysis. It is characterised by voiding and storage symptoms of 
variable severity and the progression of this disease may lead to recurrent urinary tract infections, 
bladder calculi or urinary retention.(135, 136) BPH is intimately related to ageing and although it 
is not life threatening, the effect of the lower urinary tract symptoms on patient quality of life can 
be significant.(137, 138) Histologically, BPH represents specific deviations in architecture rather 
than simply an increase in cell population. The macroscopic identification of hyperplastic 
glandular acini separated by fibrous stroma in a nodular pattern confirms the pathological 
diagnosis. In the transitional zone (TZ), glands may display architectural complexity and papillary 
infolding. The acini are microscopically tightly packed, lined by tall columnar epithelial cells with 
small basal and the epithelium has a distinct double layer of secretory and basal cells. In the BPH 
cells the nuclei remain aligned in a single row, which differs from Prostatic intraepithelial 
neoplasia (PIN), where the nuclei are irregularly arranged. The cytoplasm is clear and abundant. 
(137, 139) 
Prostatic intraepithelial neoplasia (PIN) is diagnosed when there are changes in how the prostate 
cells look under the microscope, but the abnormal cells do not look like they have grown into 
other parts of the prostate.(140, 141) PIN is often divided into low-grade and-high grade. The low-
grade begin to develop at an early age and do not necessarily indicate that the patient will 
develop prostate cancer. If a finding of low-grade PIN is reported on a prostate biopsy, the follow-
up for patients is usually the same as if nothing abnormal was seen. In the cases of a high-grade 
PIN there is about a 20% to 30% chance that cancer may already be present somewhere else in 
the prostate gland. Therefore, these cases are watched more carefully and a prostate biopsy may 
be repeated, especially if the original biopsy did not take samples from all parts of the 
prostate.(140, 142) 
In the atypical small acinar proliferation (ASAP) or just atypia, the cells look like they might be 
cancerous when viewed under the microscope, but there are too few of them to be sure. 
Therefore, there is a high chance that cancer is also present in the prostate and an appropriate 
follow-up of the patients is necessary. (143, 144) 
In cases of proliferative inflammatory atrophy (PIA), the prostate cells look smaller than normal 
and signs of inflammation are present. PIA is not cancer but is believed that it may sometimes 
lead to high-grade PIN or to prostate cancer directly.(145) 
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3.7. Magnetic Resonance Imaging, Computed Tomography and Nuclear Medicine 
Routinely, clinical staging of patients with prostate cancer is performed with cross sectional 
imaging techniques such as magnetic resonance imaging (MRI) and computed tomography (CT).  
The CT scan (or CAT scan) is a special kind of x-ray test that gives detailed, cross-sectional images 
of your body. A CT scanner takes many pictures of the part of the body being studied, and not just 
one picture like a standard x-ray, creating detailed images of the soft tissues in the body. CT scans 
rarely provide useful information about newly diagnosed prostate cancers, so it is not always 
performed at baseline in men with a PCa diagnosis. However, this test can help tell if the prostate 
cancer has spread into nearby lymph nodes, which made it the usual first-line investigation for 
detecting soft-tissue metastases. (146-148) 
The MRI scan uses radio waves and strong magnets instead of x-rays and is a technique that can 
be helpful in looking at prostate cancer.(149) MRI scans can produce a very clear picture of the 
prostate and show whether the cancer has spread outside the prostate into the seminal vesicles 
or other nearby structures. To improve the accuracy of the MRI, a probe called endorectal coil can 
be used to help in the detection of extracapsular disease. However, in the overall context of 
patient assessment, this test adds little to clinical staging and is currently predominantly a 
research technique. (147, 149, 150) 
Finally, technetium labelled phosphate radioisotope bone scanning is used for diagnosing bone 
metastases and is a sensitive method for prostate cancer staging. Routine bone scanning is usual 
prior to treatment, as a bone scan at this time serves as a baseline reference for subsequent 
monitoring. Sites of increased radio-tracer uptake are those with greater metabolic activity, called 
‘hot-spots’, and a malignant cause has to be differentiated from non-malignant diagnoses. The 
predilection for PCa metastases to strongly favour the axial skeleton, with a much less common 
limb involvement (apart from upper femora), helps in this differentiation.(147, 150) 
There are some other techniques, which use is not yet well established, such as positron emission 
tomography (PET) and ProstaScint scanning.(149, 150) Like the bone scan, the ProstaScint scan 
uses an injection of low-level radioactive material to find cancer that has spread beyond the 
prostate. The material used for the ProstaScint scan is attracted to prostate cells in the body, 
since it contains a monoclonal antibody specific to the prostate-specific membrane antigen 
(PSMA), a substance found at high levels in normal and cancerous prostate cells. This test can find 
prostate cancer cells in lymph nodes and other soft (non-bone) organs. However, the test is not 
always accurate, with 70-80% sensitivity in detecting lymph node metastases and the results can 
sometimes be confusing.(150) 
 
3.8. TNM Staging of the Prostate 
Staging is a method of describing the extent of local and distant spread of a tumour, being very 
important in clinical practice since it enables an assessment of prognosis and thus guides patient 
management.  
In the twentieth century, different staging systems for PCa were established; being the first 
internationally accepted staging system introduced by Whitmore in 1956, which classified the 
stages in letters (A-D). Posteriorly, Jewett had modified this staging system, subdividing level B. (2) 
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In 1950, staging systems for solid tumours began to consider the TNM (Tumour – Lymph node –
Metastasis) classification to analyse patient’s prognosis and to determine the tumour’s definite 
level of development.(2, 151) Currently, TMN staging can be made either based on examination 
and radiological finding (clinical) or based on pathology specimen analysis (pathological). The 
clinical and pathological stages are designated by the letters ‘c’ and ‘p’, respectively, preceding 
the stage denotation. The T-stage describes the extent of local spread and is assessed by DRE and 
imaging; the N-stage is assessed by imaging or biopsy of suspicious lymph nodes; and the M-stage 
is assessed by examination, imaging and biochemical investigations. Within each category of TNM, 
there are several sublevels based on tumour volume or extent (T1–T4), amount and/or size of 
lymph node metastases (N0–N3), and distant metastases (M0–M1). (151, 152) The Table 4 
describes the definitions of each stage.  
The development and improvement of staging systems is a complex procedure and clinical 
subspecialties are now focusing on the improvement of staging systems for different neoplastic 
disease to precisely demonstrate each patient’s prognosis. 
 
T – Primary Tumour  
Tx Primary tumour cannot be accessed 
T0 Evidence of primary tumour 
T1 Clinically inapparent tumour not visible by imaging 
T1a Tumour incidental histological finding in 5% or less of tissue resected 
T1b Tumour incidental histological finding in more than 5% of tissue resected 
T1c Tumour identified by needle biopsy 
T2 Tumour confined within the prostate 
T2a Tumour involves one half of one lobe or less 
T2b Tumour involves more than half of one lobe, but not both lobes 
T2c Tumour involves both lobes 
T3 Tumour extends through the prostatic capsule 
T3a Extracapsular extension (unilateral or bilateral), including microscopic bladder neck involvement 
T3b Tumour invades seminal vesicle(s)  
T4 Tumour is fixed or invades adjacent structures, other than seminal vesicles: external sphincter, 
rectum, levator muscles, and/or pelvic wall 
N – Regional Lymph Nodes 
Nx Regional lymph nodes cannot be accessed 
N0 No regional lymph node metastasis 
N1 Regional lymph node metastasis 
M – Distant Metastasis 
Mx Distant metastasis cannot be accessed 
M0 No distant metastasis 
M1a Non-regional lymph node(s) 
M1b Bone(s) 
M1c Other site(s) 
Table 4 TMN staging of adenocarcinoma of the prostate. Adapted from (151) 
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3.9. Molecular Profiling Techniques for Prostate Cancer 
One of the challenges in diagnosing prostate cancer is the heterogeneity of the disease 
phenotypically. As described before, alterations occur in cancer cells at many levels; so many 
methods have been used to identify potential markers for PCa, including analysis of gene 
expression (microarrays and quantitative PCR) and protein marker changes between disease and 
non-disease states (histopathology, Mass-spectrophotometry). 
In samples which are difficult to classify, most commonly prostatic biopsies, 
immunohistochemistry is used to determine the presence of prostate cancer. A high molecular 
weight basal cell-specific cytokeratin, which preferentially stains basal cells, is useful in the 
diagnosis of small acinar carcinoma, confirming the presence of basal cells or absence. The use of 
specific antibodies for prostate specific markers such as PSA or PAP has a limited application in 
identifying prostate tumours, since they are present in both primary and secondary lesions and 
also sometimes in benign glands.(153) Some neuroendocrine markers can also be used to identify 
prostate tumours, since they are focally expressed in many adenocarcinomas, but their role in 
carcinoma is unknown. 
There are many published papers describing genetic alterations present in PCa; some that appear 
to be random and others seem to be consistently present. The DNA micro array technology has 
been used to quantitatively elucidate genes expressed by prostate cancer cells. This technique 
enable identify genes that could act as biomarkers for PCa.(154, 155) However, the heterogeneity 
of prostate tissue and conflicting results are limiting characteristics in the establishment of 
markers as providers of predictive or prognostic information.  
 
3.10. Management of Patients with Prostate Cancer 
As already mentioned before, the routine PSA-based detection has increased the percentage of 
newly-diagnosed cases potentially curable by surgery or radiotherapy. However, a considerable 
proportion of patients are not candidates for such intervention, being unresectable (locally-
advanced) disease, ‘poor tumour pathology’, the presence of demonstrable metastases and 
advancing age in association with a limited life-expectancy, common exclusionary factors.(156) As 
prostate cancer is has a relatively slow growing; only men with at least a 10-year life expectancy 
are usually considered for aggressive, potentially-curative treatment. Radical retropubic 
prostatectomy (RRP) is not offered to men with cT3 or cT4 disease. However, radiotherapy in 
combination with androgen deprivation therapy has a more recognised role in locally advanced 
disease, especially with neo-adjunctive or adjunctive androgen suppressive treatment.(157-159) 
Also, a proportion of patients with cT1 or cT2 tumours that are upstaged to pT3 at time of surgery 
have been reported to have durable cancer remissions.(160) 
There are 3 management options for cases of a clinically localised disease: those include RRP, 
radiotherapy in the form of either external beam radiotherapy or brachytherapy and watchful 
waiting. These cases also need on-going support and counselling and to be monitored for disease 
progression and for potential future therapeutic intervention.  
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4. Fourier Transform Infrared Spectroscopy – a new diagnostic modality of Prostate Cancer 
Since its commercial introduction in 1970 infrared (IR) spectroscopy has been recognized as a 
non-destructive, label free, and highly sensitive and specific analytical method with many 
potential useful applications in different fields of biomedical research and in particular cancer 
research.  
In the past decades many technological improvements have been made to facilitate biomedical 
applications of Fourier Transform Infrared Spectroscopy (FTIR) extensively reviewed in which has 
been successfully applied to samples from a variety of cell lines(161), blood cells(162, 163), and 
tissues(164, 165), including cervix(166), breast(167), prostate(168-170), lung(171), colon(172, 
173), brain(174, 175), skin(176, 177), esophagus(178), liver(179), lymph system(180, 181) and 
stem cells(182-184). The results of many studies have clearly indicated that FTIR associated with 
the use of some appropriate statistical data analysis methods has a strong accuracy in classifying 
normal and malignant tissues/cells.(185) However, the application of FTIR to cancer research and 
clinical diagnostics continues to be “under strong development” or “promising”. 
 
4.1. FTIR, Cancer and Prostate Cancer 
The development of most cancers is not yet fully understood, but it is now recognised that many 
develop through pre malignant stages. Thus, the most important factor in the prevention of 
cancer is early detection, facilitating eradication of these pre-malignant abnormal cells prior to 
systemic invasion. Therefore, there is great clinical need for techniques that can detect these pre-
malignant biochemical changes that can advance to cancer. Currently, cancer diagnostics is highly 
reliant on histopathology, which is somewhat subjective, associated with inter-observer 
disagreement and in the main part relies on morphological information. Sampling errors can 
severely restrict the effectiveness of biopsy and lead to the unnecessary removal of tissue.(186) 
The ideal diagnostic test would provide rapid, non-invasive diagnosis at the point-of-care with 
high throughput and without prior tissue processing.  
Since the early 1990s several groups have used FTIR spectroscopy to distinguish normal from 
neoplastic tissues. Comprehensive studies using Fourier transform infrared (FTIR) have 
demonstrated potential for rapid, high resolution, non-destructive, molecular histopathology 
without staining and possibly additional prognostic information. In combination with 
chemometric techniques, spectroscopy can provide a more objective diagnostic assessment in 
comparison to the subjectivity associated with histopathology.(186) Biochemical changes 
extracted from the spectral dataset enable the researcher to potentially detect molecular changes 
that precede any morphological change, thus enabling earlier diagnosis of tissue dysplasia. 
Development of technology and analytical methods is now enabling moves toward diagnosing 
neoplastic change at progressively earlier stages and potential to do so in vivo.  
 
Prostate tissue is complex and heterogeneous and the diagnosis of prostate cancer (PCa) in 
individual patients can be problematic, which can lead to inappropriate treatment. The Gleason 
grading system, which is used by pathologists as an enumeration of the disease state based on the 
appearance of fixed and stained tissue sections, has many well-recognized flaws, as already 
mentioned before.(32, 33, 187, 188) Therefore, the limitation with these diagnostic modalities has 
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led to an interest in the development of spectroscopic analytical techniques for the diagnosis of 
PCa. FTIR analysis might provide an improved diagnosis of cancer and could also facilitate the 
identification of tumours with aggressive biopotential. Many published studies already showed 
that FTIR methods can discriminate tumours that are clinically confined to the prostate from 
those that are clinically invasive.(168, 169, 188-191) Infrared spectra of biomolecules allow the 
measurement of complex molecular vibrational modes that contain valuable information on 
changes occurring due to diseases such as cancer.(186, 188, 190) Thus, when used together with 
pathology reports, FTIR methods could lead to an increase in the accuracy of diagnosis. 
 
B. Significance of the Study 
Prostate cancer (PCa) is the second most common cancer among men and the fifth most common 
cancer overall, being the sixth leading cause of death from cancer in men.(14, 15) 
Despite the dramatic rise in PCa incidence over the last decade and its demonstrated clinical 
significance, its etiology and natural history remain poorly understood. Currently, the diagnosis of 
PCa only relies on histopathological analysis. However, the prostate tissue is complex and 
heterogeneous and the pathological interpretation of prostate specimens can be time consuming 
and subjective due to inter observer variation.(32, 33, 187, 189) Therefore, there is an urgent 
need for more sophisticated and objective techniques that can detect these biochemical changes 
that can advance to cancer, improving the cost, speed and accuracy of prostate cancer diagnosis. 
FTIR is a recognized non-destructive, label free, highly sensitive and specific analytical method 
which might provide an improved diagnosis of PCa and could also facilitate the identification of 
tumors with aggressive biopotential.(189) 
This pilot study intends to investigate the potential application of FTIR as a tissue diagnostic 
technique to complement histopathology and to identify where FTIR may create a niche in clinical 
practice. The small sample size of this study makes difficult to define if the obtained data 
constitute a biologically relevant effect. Therefore, the present study constitutes an exploratory 
study or pilot study that will generate hypotheses for more intensive and targeted confirmatory 
experiments in the future. 
 
The exploratory study aims to: 
1) observe if FTIR analysis can be correlated to the histopathological analysis of prostate 
tissue samples;  
2)  test if FTIR together with multivariate analysis can distinguish objectively normal prostate 
tissue from PCa tissue samples; 
3) test if FTIR together with multivariate analysis can classify PCa tissues samples; 
4) identify spectroscopic signals responsible for the discrimination and classification of 
prostate tissue samples. 
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Chapter two  
This chapter starts with an overview of the Fourier Transform Infrared 
Spectroscopy principles, including the theory of the infrared spectroscopy 
and the FTIR equipment. The second part of this chapter includes the sample 
characterization and the methods used in this study are described.  
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C. Method Overview 
 
5. Infrared Spectroscopy 
Infrared (IR) Spectroscopy is a powerful analytical tool to probe the structure of lipids, nucleic 
acids, carbohydrates and the primary and secondary structure conformation of proteins. It can 
also be used to study the composition of other complex biological materials such as body fluids, 
cell cultures and tissues, as we did in this study. IR spectroscopy is a technique based on the 
vibrations of the atoms of a molecule. An infrared spectrum is commonly obtained by passing 
infrared radiation through a sample and determining what fraction of the incident radiation is 
absorbed at a particular energy. The energy of each peak in an absorption spectrum  corresponds 
to the frequency of a vibration of a part of a sample molecule.(192) 
Infrared (IR) Spectroscopy enables the rapid, non-destructive molecular specific interrogation of 
clinical samples with high throughput. The ability to undertake studies on samples already 
characterized provide information on patient outcomes, enabling any prognostic information 
within the IR data to be elucidated as well as correlations with histopathology.(189) 
 
5.1. Theory of Molecular Spectroscopy 
The electromagnetic waves contained within a continuous range of frequencies known as the 
electromagnetic spectrum have been extensively used in cancer research and diagnosis. These 
waves differ from each other in the length and frequency. The frequency of vibration, ν, is the 
number of wave cycles that pass through a point in one second and it is measured in Hz. The 
wavelength, λ, is the length of one complete wave cycle and it is often measured in cm 
(centimeters). Wavelength and frequency are inversely related. The energy is related to 
wavelength and frequency, being directly proportional to frequency and inversely proportional to 
wavelength.(192-194) The energy values fit the quantized vibrational transitions of intra- and 
intermolecular bonds of bonded atoms in molecules and, therefore, photons can be absorbed by 
molecules that are in periodic (sinusoidal) motion.(189) 
The infrared (IR) radiation is invisible to the naked eye and comprises an interval of 
electromagnetic spectrum between the red end of the visible region (λ~780 nm) and the 
beginning of microwaves region (λ=1 mm). The most commonly used spectroscopic unit in the IR 
region is the reciprocal of the wavelength, 1/λ, called wavenumber, with unit of reciprocal 
centimeter (cm-1). The spectrum has dimension of wavenumbers extending from ~14000 cm-1 to 
~4 cm-1, and three regions of increasing wavenumbers have been recognized within this interval: 
near-IR (14 000 to 4 000 cm-1), mid-IR (4 000 to 400 cm-1), and far-IR (400 to 4 cm-1) – see Figure 
6.(192, 193, 195, 196) 
In IR absorbance spectroscopy the loss of IR radiation transmitted through a sample across an 
interval of frequencies of electromagnetic spectrum is measure and near-IR spectroscopy, mid-IR 
spectroscopy, and far-IR spectroscopy (THz spectroscopy) can be performed depending on the 
selected interval of wavelengths. Molecular spectroscopy is the quantitative and qualitative 
analysis of the spectra produced by this interaction between the radiation and the sample.(189, 
196) 
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Figure 6 The electromagnetic spectrum, showing the three infrared (IR) regions. Adapted from (197, 198) 
 
5.2. Molecular vibrations 
Infrared spectroscopy is an absorption spectroscopy in which IR radiation is absorbed by organic 
molecules and converted into energy of molecular vibration. An organic molecule is exposed to 
infrared radiation and when the radiant energy matches the energy of a specific molecular 
vibration, absorption occurs. In other words, if incident IR radiation corresponds to the 
appropriate ΔE (amount of energy emitted or absorbed by the system) to cause a molecule to be 
promoted to a higher energy state, it will be absorbed. The change in energy state is represented 
in infrared spectroscopy by a change in vibrational mode.(192, 194) 
Therefore, infrared spectroscopy is possible because molecules are not static; they 
vibrate/oscillate when they interact with radiation. A molecule in its resting stable energy state 
will have a number of degrees of freedom - the potential to change position in space and rotation. 
Being N the number of atoms in the molecule, a molecule consisting of N atoms has a total of 3N 
degrees of freedom, corresponding to the Cartesian coordinates of each atom in the molecule. 
The number of degrees of freedom in a polyatomic nonlinear molecule is: 3N-6 (3 translational 
and 3 rotational) and in a linear molecule is: 3N-5 (3 translational and 2 rotational). For example, 
oxygen (O2) is a diatomic linear molecule with only one stretch vibration ((3x2)-5 = 1). The 
nonlinear molecule water (H2O) has 3 degrees of freedom ((3x3)-6 = 3).(194-196) 
The simplest types (modes) of vibrational motion in a molecule that are infrared active (give rise 
to absorptions) are the stretching and bending modes. Stretching (axial deformation) involves a 
change in the bond length. Some bonds stretch in-phase (symmetrical stretching) or out-of-phase 
(asymmetric stretching), and, in general, asymmetric stretching occur at higher frequencies than 
symmetric stretching – see Figure 7.(193-196) Bending (angular deformation) involves a change in 
the bond angle in relation to an arbitrary coordinate ensemble of the molecule. There are four 
types of bending vibrations: two of them are bending vibrations in one plane, which involve 
changes in bond angles and but leaving bond lengths unaltered, and they include scissoring 
(symmetrical bend in-plane) and rocking (asymmetrical bend in-plane); the other two are bending 
vibrations out of plane, in which one atom oscillates through a plane defined by at least three 
neighbouring atoms, and they include wagging (symmetrical bend out-of-plane) and twisting 
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(asymmetrical bend out-of-plane) – see Figure 7. Also, bending vibrations occur at lower 
frequencies than corresponding stretching vibrations.(192, 194-196) 
 
 
Figure 7 The vibrational modes of stretching and bending. Adapted from (192) 
However, not all the molecular vibrations are infrared active i.e. show infrared absorptions. The 
key to a substance being infrared active is that an electric dipole moment of the molecule must 
change during the vibration. This change in moment is stimulated by the electrical field 
interaction with the molecules’ dipole moment and may be either parallel or perpendicular to the 
line of symmetry axis. HCl, NO, and CO are examples of heteronuclear diatomic molecules that are 
infrared active. The dipole moment of such molecules changes as the bond expands and 
contracts. By comparison, H2, N2, and O2 are examples of homonuclear diatomic molecules that 
are infrared inactive because its dipole moment or net charge remains zero no matter how long 
the bond and therefore there will be no detectable IR activity.  Stretching vibrations of N2, O2 as 
well as of many other non-IR active modes can be detected by Raman spectroscopy.(192, 195, 
196)  
Furthermore, the same molecule can have vibrations that are IR active and others inactive. For 
example, if we consider carbon dioxide (CO2) as a linear molecule with essentially one degree of 
freedom in the mode of vibration ‘symmetric stretch’. The molecule is symmetrically stretched 
and compressed with both CO bonds changing simultaneously. Therefore, the dipole moment 
remains unchanged throughout and this vibration is IR inactive. However, if we consider CO2 in 
the linear asymmetric stretch mode, there is a periodic alteration in dipole moment and this 
vibration is IR active.(192, 194-196)  
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A complex molecule will have a large number of vibrational modes involving the whole molecule. 
Infrared spectroscopists have defined frequencies at which characteristic bond vibrations will 
occur when known chemical groups are present within a sample. 
 
5.3. The Infrared spectrum 
Figure 8 shows two typical IR spectra. As we can see, the wavenumber, plotted on the X-axis, is 
proportional to energy, being the highest energy vibrations on the left. The left spectrum is 
plotted as T on the Y-axis, being T the percentage transmittance (%T) with 100% at the top of the 
spectrum. Absorption of radiant energy is therefore represented by a “trough” in the curve: zero 
transmittance corresponds to 100% absorption of light at that wavelength. Band intensities can 
also be expressed as absorbance (A), from 0 to 1. Absorbance is the logarithm, to the base 10, of 
the reciprocal of the transmittance – see Figure 8. It comes down to personal preference which of 
the two modes to use, but the transmittance is traditionally used for spectral interpretation, while 
absorbance is used for quantitative work and multivariate analysis. For this study we use spectra 
plotted as absorbance (A).(192-194)  
The complexity and the wavenumbers of the peaks in the spectra give information about the 
molecule. The complexity is useful to match an experimental spectrum with that of a known 
compound with a peak-by-peak correlation. The wavenumbers (or frequencies) at which an 
organic molecule absorbs radiation give information on functional groups present in the 
molecule.  
Certain bonds absorb energy at the same wavelength range, regardless of the structure of the 
molecule, and give rise to bands at approximately the same frequencies. For example the C=O 
stretch of a carbonyl group occurs at approximately 1700cm-1 in ketones, aldehydes and 
carboxylic acids. This is the principle upon which infrared spectroscopy can be used for chemical 
identification. Spectroscopists refer to the fingerprint region of a spectrum (<1500cm-1) which is 
unique for a molecule and the functional group region (1500-4000cm-1) which may be similar for 
molecules within the same group. With the help of tables which correlate frequencies with 
functional groups is possible to analyse a spectrum.(192) 
 
 
Figure 8 The IR spectrum of octane, plotted as transmission (left) and absorbance (right). Adapted from (193) 
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5.4. FTIR Instrumentation  
All modern IR spectrometers use Fourier transform (FT) and are composed of the following 
common elements: an infrared light source, an interferometer, a single element detector, an 
optical system with a motorised x-y-z stage and a computer to process the data. The radiation 
emerging from the source is passed through an interferometer to the sample before reaching a 
detector. (189, 192, 193) 
FTIR spectroscopy is based on the idea of the interference of radiation between two beams to 
yield an interferogram. An interferogram is a signal produced as a function of the change of path 
length between the two beams. The two domains of distance and frequency are interconvertible 
by the mathematical method of Fourier transformation. 
The four arms Michelson interferometer, which is the most common interferometer used, 
consists of a top arm that contains the infrared source and a collimating mirror that collects the 
light from the source and makes its rays parallel; a bottom arm that contains a stationary mirror; 
a right arm that contains a moving mirror; and a left arm that contains the sample and detector. 
At the centre of the interferometer there is a semi-reflecting film, the beamsplitter, which bisects 
the planes of the two mirrors.(192, 193, 199) When a parallel beam of radiation is directed from a 
source to an interferometer the following happens: the beamsplitter splits the beam into two 
separate light paths. 50% of the incident radiation is reflected to one of the mirrors and the 
remaining 50% is transmitted to the other mirror. The radiation reflected from these mirrors 
comes back along the same path to the beamsplitter where it recombines and interferes. The 
recombinant radiation that emerges from the interferometer at 90º to the input (IR) beam is 
called the transmitted beam.(189, 192) This is the beam detected in FTIR spectrometry, as it will 
interact with the sample and then will reach the detector – see Figure 9. 
The moving mirror in the interferometer produces an optical path difference between the two 
arms of the interferometer. Destructive interferences in the case of the transmitted beam or 
constructive interferences in the case of the reflected beam are generated. The resultant 
interference pattern is called an interferogram. This represents the summation of all the cosine 
functions of all the individual wavelengths present in the source and zero path difference (ZPD) 
positions where all interferences will be in phase (the centre-burst).(189)  
 
 
Figure 9 Scheme of an interferometer of a Fourier transform spectrometer. Adapted from (192) 
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The application of the Fourier transformation will convert this interferogram into an IR single-
beam spectrum where the number of peaks will reflect the number of detectable components in 
the sample. The intensity in peaks, reflecting the amount of different molecular bonds absorbing 
in specific regions of the IR spectrum, will be in relation with the relative abundance of different 
sample constituents. The spectral resolution is the minimum wavenumber difference that can be 
distinguished between two lines in a spectrum. 
The FT-IR absorbance spectrum is one of the most information-rich and concise way to represent 
the whole “…omics” of a sample and, as such, fits all the characteristics for the development of a 
clinically useful biomarker.(189) 
 
5.5. Sampling Method: Attenuated total reflectance (ATR) spectroscopy 
Despite the traditional sampling approach in infrared (IR) spectroscopy have been the 
transmission techniques, various reflectance and microsampling techniques have emerged as 
valuable methods for samples that are difficult to analyse by the conventional transmittance 
methods.(192, 194)  
The reflectance method attenuated total reflection (ATR) spectroscopy is especially useful for 
samples which do not let light through either because they are highly absorbing or they cannot be 
cut into thin enough sections. ATR spectroscopy utilizes the phenomenon of total internal 
reflection. An ATR objective containing an ATR crystal - made of an infrared transparent material 
like diamond used in this study - fitted to the FTIR spectrometer. The ATR crystal is used to probe 
the sample and must be in contact with the sample to work.(192) The beam of radiation entering 
the ATR crystal will undergo total internal reflection when the angle of incidence at the interface 
between the sample and crystal is greater than the critical angle2. The beam penetrates a fraction 
of a wavelength beyond the reflecting surface and loses energy at the wavelength where the 
material absorbs. Therefore, there is a reflection loss (evanescent waves) and a reflection loss 
spectrum can be created and adjusted for the depth of penetration of the sample.(189, 192, 194) 
The resultant attenuated radiation is measured, plotted as a function of wavelength by the 
spectrometer and gives rise to the absorption spectral characteristics of the sample.(189) 
Different designs of ATR cells allow both liquid and solid samples to be examined. In this study we 
use the Golden Gate™ ATR – see Figure 10. 
The ATR technique requires little sample preparation. However, it can be time consuming when 
used with biological tissues like in this study, as the objective had to be cleaned between spectral 
measurements at different points. 
 
                                                        
2
 Function of the refractive indices of the two surfaces. 
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Figure 10 Golden Gate™ ATR. Adapted from (200) 
 
5.6. Advantages of the method 
FTIR instruments have several significant advantages over older dispersive instruments. 
The main advantage of rapid-scanning instruments is the ability to increase the signal-to-noise 
ratio (SNR) by signal-averaging, leading to an increase of signal-to-noise proportional to the 
square root of the time. This is the Fellgett (or multiplex) advantage and is due to an 
improvement in the SNR per unit time, proportional to the square root of the number of 
resolution elements being monitored. This results from the large number of resolution elements 
being monitored simultaneously. Furthermore, because FTIR spectrometry does not require the 
use of a slit or other restricting device, the total source output can be passed through the sample 
continuously. This results in a substantial gain in energy at the detector, hence translating to 
higher signals and improved SNRs. This is known as Jacquinot’s (or throughput) advantage.(192, 
194) 
Another strength of FTIR spectrometry is its speed advantage. The mirror has the ability to move 
short distances quite rapidly, and this, together with the SNR improvements due to the Fellgett 
and Jacquinot advantages, make it possible to obtain spectra on a millisecond timescale.(192) 
 
D. Methods of study 
 
6. Prostate Tissue Collection 
The samples of prostate tissue selected for the present study were provided by the Laboratory of 
Signal Transduction of the Center for Cell Biology of University of Aveiro in the context of the 
project PTDC/QUI-BIQ/118492/2010: "Identification of a novel TGFbeta cascade regulated by a 
Protein Phosphatase 1 complex" from the research team Margarida Sâncio Da Cruz Fardilha and 
Sandra Maria Tavares da Costa Rebelo, Luis Korrodi Mineiro Marques Gregório and Joana Vieira 
Silva. The clinical data was collected by the Urologists António Patrício and Nuno Maio. 
 
With full ethical committee approval of the Infante Dom Pedro Hospital, tissue was collected at 
routine operating lists at the Urology Service of the Infante Dom Pedro Hospital in Aveiro from 8 
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consenting patients undergoing radical prostatectomy. After surgery, six to eight biopsy cores 
were collected from 8 patients with prostate cancer (PCa). A portion of normal prostate tissue 
and a portion of PCa tissue, with approx. 5 mm in thickness each, were sectioned from each 
patient. A total of sixteen tissue biopsy specimens were included in the present study – see Table 
5. 
No tissue preparation or fixation was necessary and after the collection the samples were stored 
in a -80ºC freezer.  
 
Number of patients Number of samples Benign Malignant 
8 16 8 8 
Table 5 Samples included in this study. 
6.1. Sample Characterization 
Prostate biopsy samples were collected from radical prostatectomy pieces of 8 patients with ages 
between 54 and 66 at Infante Dom Pedro Hospital in Aveiro. Patients were attending for radical 
prostatectomy because they were suspected to have prostate cancer on the basis of either an 
initial elevated PSA blood test or abnormal digital rectal examination (DRE) or both – see Table 6. 
All patients gave consent for extra biopsies to be taken and used for purely research purposes. 
The samples were stored in a -80°C freezer after collection. Besides the initial PSA reported, prior 
to TRUS biopsy and the DRE results, was also recorded the histologic analysis, including the 
Gleason grade at the time of the prior biopsy and the Gleason grade of the surgical piece, the 
TMN staging and further considerations about the prostate characterization and pathology. The 
Table 6 details the sample characterization for the 8 patients of this study, including the PSA level, 
the Gleason grade and the final formal TRUS biopsy histology. 
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Patient Age Initial PSA Gleason (Biopsy) 
Gleason (Surgical 
Piece) 
Pathology TMN staging Prostate characterization (Surgery) DRE/Eco Notes 
1 (25/09/12) 64 4,93 7 (3+4) Bilateral 7 (3+4) Bilateral 
- 25% of the gland 
affected 
pT2cN0 
- Prostate of 35g 
- Negative Margins 
Eco without 
alterations 
- 
2 (02/10/12) 66 8 8 (4+4) Left 8 (4+4) Left 
- 20% of the gland 
affected 
- Extracapsular extension 
pT3aN0 
- Prostate of 27g 
- Negative Margins 
Eco with a 7,3 mm 
nodule at the left 
- 
3 (16/10/12) 64 7,55 7 (3+4) Right 7 (4+3) Bilateral 
- 20% of the gland 
affected 
- Extracapsular extension 
at the right 
pT3aN0 
- Prostate of 36g 
- Negative Margins 
Eco with a 5 mm 
nodule of the 
peripheral zone at 
the left; 
heterogeneity at the 
right 
- 
4 (23/10/12) 64 6,24 7 (3+4) Right 7 (3+4) Right 
- 10% of the gland 
affected 
pT2aN0 
- Prostate of 59g 
- Negative Margins 
Eco showing 
peripheral 
heterogeneity 
- 
5 (30/10/12) 58 51,2 7 (4+3) Bilateral 7 (3+4) Bilateral 
- 35% of the gland 
affected 
pT2aN0 
- Prostate of 32g 
- Negative Margins 
- DRE with prostate 
hardening at the left 
(suggesting tumour) 
- Eco without define 
nodules 
Extremely aggressive 
tumour, occupying 
large part of the 
prostate 
6 (06/11/12) 54 9,6 9 (5+4) Right 9 (5+4) Bilateral 
- 20% of the gland 
affected 
- Focal extracapsular 
extension 
pT3aN0R1 
- Prostate of 30g 
- Positive Margins 
Eco showing diffuse 
heterogeneity of the 
peripheral zone at 
the right with 
18x10mm 
Complementary 
radiotherapy (RT) 
7 (09/01/13) 66 6,41 7 (3+4) Right 7 (3+4) Bilateral 
- 5% of the gland 
affected 
pT2cN0 
- Prostate of 80g 
- Negative Margins 
Eco showing BPH 
exceeding 60g and 
with a 12 mm 
nodule at the right 
Patient in androgen 
deprivation therapy 
(Casodex) – initiated 3 
months before surgery 
8 (28/02/13) 59 4,08 7 (4+3) Right 7 (4+3) Bilateral 
- 65% of the gland 
affected 
- Focal extracapsular 
extension 
pT3aN0 
- Prostate of 30g 
- Negative Margins 
DRE with prostate 
hardening at the 
right 
- 
Table 6 The characteristics of the prostate specimens included in this study.
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7. Spectroscopy procedure 
 
Mid-infrared spectroscopy was used to obtain the spectra. Therefore, the prostate sample was 
placed in the path of the IR beam light between the source and the detector and absorbed only 
the frequency of mid-IR that coincides with the frequency of the vibration allowing the sample 
molecules to enter in a resonant vibration status. Mid-IR absorbance spectroscopy plots the 
recorded intensity of absorption bands versus an interval of wavenumbers, from 4000 to 400 cm-
1, which corresponds to changes of vibrational energy levels from the ground level to the first 
energy level (E0→E1) in molecules.(189)  
Multivariate analysis was performed in order to infer classification and discrimination between 
prostate cancer tissue and normal prostate tissue. Also relevant spectroscopic regions and 
corresponding assignments to chemical functional groups have been identified.  
 
7.1. Spectral acquisition 
Before spectroscopic analysis, samples of prostate tissue that were stored at -80ºC were thawed 
at room temperature. Perkin-Elmer Spectrum BX FT-IR spectrometer was used to acquired spectra 
in the 4 000 to 900 cm-1 range at 8 cm-1 resolution with 64 co-added scans. Room temperature 
and humidity were always controlled and have been kept at ± 25ºC and ± 37% respectively. The 
acquisition of background single beam was performed against air (with the empty crystal) before 
each 5 mm thickness prostate tissue specimen has been posed on the ATR diamond crystal. The 
tissue sample is placed onto the crystal in order to fully cover it. During the spectral acquisition all 
the samples experienced the same constant pressure, characteristic of the golden gate 
equipment, which increase the adhesion to the crystal and decrease the spectral artifacts. The 
crystal was carefully cleaned with water between the spectral acquisitions of each sample. 
The strong absorption of mid-infrared radiation by water is always a problem when FTIR is used in 
biological tissues. In the attempt to reduce this problem the sectioned tissue sample has been 
dried in order to see the actual biochemical composition of the tissue. The attempt of tissue 
drying was performed by simply allowing water to evaporate from the sample with the acquisition 
of six spectra (replicas) for each tissue sample. With this methodology the spectral contribution of 
water was practically eliminated and the three last acquired spectra obtained, which reached the 
possible drying stage, were the one chosen for the multivariate analysis.  
Figures 11 and 12 show an example of the six replicas obtained from a sample of normal prostate 
tissue and the six replicas obtained from a sample of prostate cancer tissue, respectively. The 
regions associated with the presence of proteins, lipids, nucleic acids and carbohydrates are 
identified in the figures.  
Given the high heterogeneity of the prostate tissue samples, replicas with discrepant values were 
removed from the analysis. The acquisition of replicates increased the confidence of results. 
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Figure 11 An example of FTIR spectra of the six replicas (R1-R6) obtained from a sample of normal prostate tissue, 
showing the regions associated with the presence of proteins, lipids, nucleic acids and carbohydrates.(189, 192, 194) 
 
 
Figure 12 An example of FTIR spectra of the six replicas (R1-R6) obtained from a sample of prostate cancer tissue, 
showing the regions associated with the presence of proteins, lipids, nucleic acids and carbohydrates.(189, 192, 194) 
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As mentioned before, in mid-IR spectroscopy bands of water are very intense and may overlap 
the bands of interest, making the interpretation and identification of differences between spectra 
very difficult in the direct spectral analysis. Analysing the three first replicas (R1-R3), for both 
normal prostate tissue and PCa tissue samples, it is easy to visually detect these difficulties. Some 
important spectroscopic regions are overlapped with H2O vibrational modes, mainly in the 3600-
3200 cm−1 region due to O–H stretching bands and near 1645 cm−1 due to H–O–H bending band – 
see Figures 11 and 12.(194) 
The problems associated with the water spectrum were minimized by simply allowing water to 
evaporate from the sample with the acquisition of replicas - tissue drying. In the three last replicas 
(R4-R6), for both samples, we observe that the bands overlapped with the water spectrum 
become much sharper as the water evaporates. The dried spectra now show important bands 
that correspond to vibrations of specific functional groups: proteins in the frequencies range of 
3310-3030 cm-1 and 1720-1250 cm-1; lipids in the range of 3020-2819 cm-1 and 1725-1740 cm-1; 
carbohydrates and nucleic acids (DNA/RNA) in the range of 1250-900 cm-1 – see Figures 11 and 
12.(189, 192, 194) The spectra obtained with the tissue drying have more spectroscopic 
information and allow a better qualitative analysis of the sample by the assignment of the peaks.  
 
8. Data processing 
Different methods can be used to analyse mid-IR spectra, from the simple direct spectra analysis 
to identify the number of peaks to “chemometrics” where mathematical, statistical, and 
computer sciences methods are applied to improve the understanding of chemical information 
contained in IR spectroscopic data. (189) 
To reduce and correct interferences that may generate irrelevant variances such as atmospheric 
water vapour and carbon dioxide, variable background absorption profiles, and differences in 
sample thickness, a pre-processing (data set pre-processing) is required. The choice of 
normalization is as crucial as the choice of the analysis technique. Rescaling the data, 
normalization makes different variables and different samples comparable allowing integrating 
them in a joint analysis. (189, 192, 196) 
The identification and assignment of spectral components (marker peaks) is generally performed 
by the so-called “group frequency approach”. The frequency of vibration of specific functional 
groups is pre-assigned according to those observed in the mid-IR spectrum of corresponding pure 
biomolecules or of mixtures of molecules and compared with those already reported in the 
literature. The application of “functional group analysis" is particularly useful for the type of 
analysis performed in this study, a qualitative analysis, since the IR spectrum of each molecule is 
unique and it can serve as a signature to distinguish among different molecules. (189, 196) 
However, the unequivocal interpretation of pre-assigned vibrational frequencies is impossible 
because the vibrations of different molecular components may overlap and the spectrum may 
reflect only the average biochemical composition.(196)  
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8.1. Multivariate Analysis 
In the results of FTIR studies many variables are observed (i.e. wavenumbers) for a number of 
individuals (e.g. normal or benign tissues). Each variable may be regarded as constituting a 
different dimension, such that if there are n variables each object may be said to reside at a 
unique position in an abstract entity referred as n-dimensional hyperspace. As this hyperspace is 
difficult to visualize, multivariate analysis will reduce the data dimensionality, creating a better 
perception of the data with the least possible loss of information. Therefore, in order to analyse 
data sets of complex biological matrices such as tissues powerful algorithms of multivariate 
statistical analysis can be applied. The use of multivariate methods makes possible to compare a 
large number of variables within a data set. (189) 
Multivariate methods can be divided into techniques of multivariate classification (pattern 
recognition techniques) and of multivariate regression. Multivariate classification can be applied 
with supervised or unsupervised pattern recognition. In supervised pattern recognition, such as 
linear discriminant analysis (LDA) and artificial neural networks (ANNS), a substantial amount of 
information is available regarding the data set. While in unsupervised pattern recognition no “a 
priori” knowledge about the data set is required. Principal-component analysis (PCA) and cluster 
analysis (CA) are examples of unsupervised pattern recognition methods which are exploratory 
for data analysis, while supervised procedures allow for a more precise classification within the 
class boundaries. Multivariate regression techniques (multivariate calibration methods), such as 
principal components regression (PCR) and partial least squares regression (PLS), are used to 
analyse one or multiple constituents in a complex sample that are subject to significantly 
overlapping analytical signals.(192, 196)  
Principal Component Analysis (PCA) is one of the most popular techniques. PCA is a non-
parametric method for extracting relevant information from confusing data sets allowing to 
identify patterns in data and to highlight their similarities and differences. With PCA the large 
number of initial variables are condensed to only a few new variables or principal components 
(PCs) those reflecting the most relevant analytical information.(189) This is performed through a 
transformation of the original data matrix with each wavenumber (variable) being a column and 
each spectrum (sample) a row. The PCA results consist in two of types of diagrams: diagram of 
factorial coordinates (scores) and diagram of factorial contributions (loadings). The scores explain 
how the spectra relate to each other, while loadings explain how the wavenumbers relate to each 
other justifying the sample distribution along the scores diagram. The first PC (PC1) exhibits the 
greatest amount of variation, PC2 the second greatest amount of variation and so on. PCA allows 
as much as possible of the variance in the data set to be described by the first significant PCs, 
while all subsequent PCs are so low as to be virtually negligible. (189, 199, 201) 
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8.2. PCA analysis 
Before the multivariate analysis, the spectra of the selected replicates were transferred through 
JCAMP-DX format into the data analysis software developed in the Institut National Agronomique 
Paris-Grignon in collaboration with the University of Aveiro. 
Principal Component Analysis (PCA) was applied to the mid-infrared spectra of prostate samples 
in order to extract the main sources of variability. PCA analysis of the FTIR-ATR spectra was 
performed to identify spectral differences between the control and the PCa group. Also some 
differences within the PCa group will be discussed. PCA was applied to several spectral regions 
according some specific characteristics related to cancer detection (Table 7). 
Two spectral pre-treatment procedures were used in the chosen spectral regions: Standard 
Normal Deviates (SNV) and second order Savitsky-Golay derivative (2D); the data set was auto-
scaled, to put all the spectra to the same scale (standardize) and increase the differences between 
them (divided by the standard deviation). 
All the direct spectral analysis of the spectra and the multivariate analysis PCA performed in this 
study will be presented and discussed in the next chapter. 
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Chapter three 
This chapter includes the results on the application of FTIR spectroscopy to 
the samples of prostate cancer (PCa) tissue and normal prostate tissue 
(controls), in order to detect spectral differences that help in the 
identification and classification of prostate tumour tissues. 
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E. Results and discussion 
 
9. Spectral Analysis 
Once the infrared spectra have been recorded, the next step is interpretation. Spectral 
interpretation is simplified by the fact that the bands that appear may be assigned to particular 
functional groups of the molecule, producing what are known as group frequencies. As already 
mentioned in the previous chapter the mid-infrared region was the one used in this study. The 
mid-infrared spectrum can be divided into four regions that are defined as follows: X–H stretching 
region (4000-2500 cm−1), triple bond region (2500-2000 cm−1), double bond region (2000-1500 
cm−1), and the “fingerprint region” (1500-600 cm−1). Table 7 shows the main regions of the mid-
infrared spectrum that can be analysed in biological samples and its relation with cancer 
detection.(189, 192, 202) 
Wavenumber (cm-
1
) Assignment 
Assigned biochemical 
component 
Relevant information 
to cancer detection 
3500-2500 X-H stretching (X is C, O or N) 
3300 N-H stretching 
Amide A peptide, 
protein 
- 
3100 N-H stretching 
Amide B peptide, 
protein 
- 
2957 
CH3 asymmetrical 
stretching 
Lipids, phospholipids 
Dysregulated lipid 
metabolism; Increased 
disorder of the 
methylene chains of 
membrane lipids 
2920 
CH2 asymmetrical 
stretching 
2872 
CH3 symmetrical 
stretching 
2851 
CH2 symmetrical 
stretching 
2000-1500 Stretching of double bonds (e.g. C=O, C=C, C=N) 
1745 C=O stretching 
Lipids, Phospholipids 
esters 
Dysregulated lipid 
metabolism; 
Membrane lipids 
(phospholipids) 
disorder 
1655 
80% C=O stretching, 
10% C-N stretching, 
10% N-H bending 
Amide I peptide, 
protein 
- 
1645 H-O-H bending Water - 
1545 
60% N-H bending, 40% 
C-N stretching 
Amide II peptide, 
protein 
- 
1500-600 The “fingerprint region” (many overlapped vibrations) 
1450 
CH3 asymmetrical 
bending 
Lipid, protein 
Increased 
hypomethylation 
1395 
CH3 asymmetrical 
bending, C=O 
Lipid, protein 
Increased 
hypomethylation 
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stretching 
1378 
CH3 symmetrical 
stretching 
Phospholipid, fatty 
acid, triglyceride 
- 
1400-1200 
N-H bending, C-N 
stretching, C=O 
stretching, C-C 
stretching and CH3 
stretching 
Amide III peptide, 
protein, collagen 
Decreased hydrogen 
bonding of the C-OH 
groups of proteins 
1245-1230 
PO2- asymmetrical 
stretching 
DNA, RNA, 
phospholipid, 
phosphorylated protein 
Increased hydrogen 
bonding of the 
phosphodiester groups 
of nucleic acids 
1170 
C-O asymmetrical 
stretching 
Ester - 
1160 and 1120 C-O stretching RNA ribose - 
1150 
C-O stretching, C-O-H 
bending 
Carbohydrates - 
1095, 1084, 1070 
PO2- symmetrical 
stretching 
DNA, RNA, 
phospholipid, 
phosphorylated protein 
Increased hydrogen 
bonding of the 
phosphodiester groups 
of nucleic acids 
1078 C-C stretching Glycogen 
Reduced glycogen 
content 
1060, 1050, 1015 C-O stretching DNA and RNA ribose - 
1050 C-O-P stretching Phosphate ester - 
1028 C-O-H deformation Glycogen 
Reduced glycogen 
content 
965 PO3
2- stretching DNA and RNA ribose - 
950 PO3
2- stretching Phosphorylated protein - 
920 C-O-P stretching Phosphorylated protein - 
Table 7 Main regions of the mid-infrared spectrum and its relation with cancer detection. Adapted from(189, 192, 202) 
 
The Table 7 reflects a bibliographic review of what have already been described in the IR 
spectroscopy field about assignments of the mid-IR spectrum related to cancer detection. 
Therefore, its content will be used to support the direct spectral analysis (Table 8) and the results 
of the multivariate analysis, presented hereafter.    
As we can see in Table 7, the mid-IR spectroscopy is a powerful tool for the study of biological 
molecules and its application to biological problems is continually expanding, as it can be used in 
the characterization of complex systems, such as diseased tissues. The main groups of biological 
molecules that can be studied in the mid-IR spectrum are: Proteins and peptides, Lipids, 
Carbohydrates and Nucleic acids. (192, 194) 
 
Proteins and Peptides: mid-IR spectroscopy can be used as an effective tool for exploring 
structural changes and functional mechanisms of bands that can be assigned to the vibrations of 
amino acids. Amino acids are important components of tissues, playing the role of the building 
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blocks of proteins. They are involved in metabolic processes at the molecular level and 
conformational changes of amino acids may modify the proper functioning of vital organs and 
cellular structure.(203) The IR spectra of proteins exhibit absorption bands associated with their 
characteristic amide group. In-plane modes are due to C=O stretching, C–N stretching, N–H 
stretching and O–C N bending and an out-of-plane mode is due to C–N stretching. There are nine 
amide bands, called amide A, amide B and amides I–VII, in order of decreasing wavenumber.(192, 
194) Amide A and B are at approximately 3300 cm-1 and 3100 cm-1, respectively, and are due to N-
H stretching. The amide I band is the most intense and useful for conformational analysis of 
proteins, occurring between approximately 1700 and 1600 cm−1. This band represents 80% of the 
C=O stretching vibration of the amide group coupled to the in-plane N–H bending and C–N 
stretching modes – see Table 7. The exact wavenumber of this vibration depends on the nature of 
hydrogen bonding involving the C=O and N–H groups, which is determined by the particular 
secondary structure adopted by the protein. Proteins generally contain a variety of domains 
containing polypeptide fragments in different conformations. Therefore, the observed amide I 
band is usually a complex composite, consisting of a number of overlapping component bands 
representing helices, β-structures, turns and random structures.(192, 194, 203) The amide II band 
represents 60% of the N–H bending, with some C–N stretching (40%). The position of the amide II 
band shifts from 1550 cm−1 to 1450 cm−1. The amide III band represents the combination of N-H 
bending and C–N stretching, with a less intensive contribution from C–C stretching and C=O 
stretching. It can be found between 1250 and 1300 cm–1 – see Table 7. Because the C=O and the 
N–H bonds are involved in the hydrogen bonding that takes place between the different 
components of secondary structure, the positions of the amides (I, II, III) bands can be sensitive to 
the secondary structure content of a protein. The amide IV-VII bands have very low intensities in 
mid-IR and are not of importance in a mid-IR analysis.(192, 194) 
 
Lipids: lipids, including fatty acids, phospholipids (lipids that contain phosphorus), cholesterol 
esters and glycerides, can be readily characterized in the mid-IR spectrum. They are important 
molecular components of membranes and are organized in bilayers of about 40–80 A in thickness, 
where the polar head group points towards the aqueous phase and the hydrophobic tails point 
towards the tails of a second layer.(192) The IR spectra of lipids can be divided into the spectral 
regions that originate from the molecular vibrations of the hydrocarbon tail, the interface region, 
and the head group. The hydrocarbon tail gives rises to acyl chain modes. The most intense 
vibrations in the spectra are the CH2 asymmetric and symmetric stretching, that gives rise to 
bands at 2920 and 2851 cm−1, respectively. The infrared bands due to the terminal CH3 groups 
gives rise at 2957 cm-1 (asymmetric stretching) and 2872 cm−1 (symmetric stretching) – see Table 
7. In the 1500–1350 cm−1 region occurs the bands due to methylene and methyl groups. At 
around 1378 cm−1 appears the symmetric deformation mode of the CH3 group.(192, 194) Spectral 
bands arising from the head group and interfacial region also provide valuable information. In the 
interfacial region the important IR bands are the ester group vibrations, particularly the C=O 
stretching bands in the 1750–1700 cm-1 region. In diacyl lipids, this region consists of at least two 
bands originating from the two ester carbonyl groups. A band at 1742 cm−1 is assigned to the C=O 
mode of the first alkyl chain with a trans-conformation in the C–C bond adjacent to the ester 
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grouping. The band 1728 cm−1 C=O wavenumber of the second alkyl chain suggests the presence 
of a gauche-band in that position.  
The wavenumber difference observed reflects the structural inequivalence of the chains, with the 
first alkyl chain initially extending in a direction perpendicular to the second alkyl chain and then 
developing a gauche-bend in order to render the two chains parallel.(194) 
 
Carbohydrates: mid-IR spectroscopy can also be used to identify carbohydrates, including sugars, 
cellulose, starch, pectins, and carrageenans. The IR bands found for this class of biomolecules are 
associated with the hydroxyl and carbonyl groups and acetal bonds. In the anomeric region of the 
mid-IR spectrum at 950–750 cm−1 is possible to distinguish the characteristic bands for α and β 
conformers or pyranoid and furanoid ring vibrations of monosaccharides and polysaccharides. 
Polysaccharides have strong bands near 3300 cm−1 because of O–H stretching. They also show a 
band near 1650 cm−1 associated with a carbonyl group (C=O stretching) and intermolecular water. 
The region 1400-800 cm-1 is associated with coupled C–O and C–C stretching and bending.(194) 
 
Nucleic Acids: the nucleic acids, deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), are vital 
molecules which carry the genetic code and are responsible for its expression by protein 
synthesis. The spectra of these molecules can be divided into the modes due to the constituent 
base, sugar and phosphate groups. The bases (thymine, adenine, cytosine, guanine and uracil) 
give rise to purinic and pyrimidinic vibrations in the region 1800-1500 cm−1. Bands in the region 
1500-1250 cm−1 are due to the vibrational coupling between a base and a sugar. In the region 
1250-1000 cm−1 sugar–phosphate chain vibrations are observed and in the region 1000-800 cm−1 
are observed sugar/sugar–phosphate vibrations.(192, 194) 
9.1. Results and discussion 
Peak position can be correlated with known verified tables of key functional group absorbance 
peak positions. Since differences in key functional group may be directly observed, a direct 
spectral analysis was performed with the intent to distinguish normal from prostate cancer (PCa) 
samples. 
Figures 13 and 14 show spectra of all samples of normal prostate tissue and PCa tissue, 
respectively. 
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Figure 13 Spectra of all samples of normal prostate tissue (controls). A.U. Arbitrary Units 
 
 
Figure 14 Spectra of all samples of prostate cancer (PCa) tissue. A.U. Arbitrary Units 
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The spectra of all samples of controls (normal prostate tissue) appear to be very similar as it is 
possible to verify that all spectra overlap, without revealing major differences. On the other hand, 
at first glance, it is possible to detect some differences when analysing Figure 13, both between 
the spectra of all samples of PCa and when comparing the spectra of all samples of controls with 
the spectra of all samples of PCa – Figures 13 and 14. The detected differences between the 
spectra of PCa may be due to the differences in tumour aggressiveness between patients. In order 
to understand these differences between the spectra and possibly distinguish the normal prostate 
samples from the PCa samples a band assignment was performed. Figures 15 and 16 show 
representative spectra of one control sample and PCa sample of a patient with an aggressive 
tumour, and representative spectra of one control sample and PCa sample of a patient with a less 
aggressive tumour, respectively. 
 
 
Figure 15 Spectra of one control sample (C) and PCa sample (T) of a patient with an aggressive tumor. A.U. Arbitrary 
Units 
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Figure 16 Spectra of one control sample (C) and PCa sample (T) of a patient with a less aggressive tumor. A.U. Arbitrary 
Units 
As already mentioned, the identification and assignment of major spectral components by 
"functional group analysis" is particularly useful in a qualitative analysis since the IR spectrum can 
serve as a signature to distinguish different samples, by the identification of specific bands of 
proteins, nucleic acids DNA and RNA, lipids, and carbohydrates.  (196) 
However, it is evident from the analysis of Figures 15 and 16 that the overall spectra appearance 
of biological samples such as prostate tissue is complex. Tissues are composed of a mixture of 
different mid-IR active molecular constituents such as membrane lipids and phospholipids, 
glycolipids, proteins and nucleic acids (DNA, RNA), and, therefore, their IR spectra contains a large 
number of bands and many of which will be impossible to confidently assign to vibration of a 
particular group, in particular analysing the “fingerprinting region”. That fact leads us to conclude 
that the unequivocal interpretation of pre-assigned vibrational frequencies is impossible because 
the vibrations of different molecular components of may overlap and the spectrum may reflect 
only the average biochemical composition.(189, 196) 
Table 8 indicate the major FTIR spectra assignments for control and PCa samples. The possible 
band assignment was made correlating the identified spectra bands with verified tables of key 
functional group absorbance band positions, and taking in account the information previously 
presented in Table 7.(164, 189) 
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Nº 
Bands of control and PCa 
spectra (cm-1) 
Assignments Tissue content 
I ~3304 N-H stretching Amide A peptide, protein 
II ~3094 N-H stretching Amide B peptide, protein 
III ~2956 
CH3 asymmetrical 
stretching 
Lipids, phospholipids 
IV ~2926 
CH2 asymmetrical 
stretching 
“Arrow” 
(only in the spectra 
of control samples) 
~2878 
CH3 symmetrical 
stretching 
V  
(only in the spectra 
of PCa samples) 
~2860 
CH2 symmetrical 
stretching 
“Arrow” 
(only in the spectra 
of control samples) 
~2852 
CH2 symmetrical 
stretching 
VI ~1750 C=O stretching Lipids, Phospholipids esters 
VII ~1645 
80% C=O stretching, 10% 
C-N stretching, 10% N-H 
bending 
Amide I peptide, protein 
VIII ~1548 
60% N-H bending, 40% C-
N stretching 
Amide II peptide, protein 
IX ~1464 CH2 bending Lipid, protein 
X ~1450 CH3 bending Lipid, protein 
XI ~1372 C-N stretching Cytosine, guanine 
XII ~1362 C-N stretching Cytosine, guanine 
XIII ~1310 
N-H bending, C-N 
stretching, C=O 
stretching, C-C stretching 
and CH3 stretching 
Amide III peptide, protein 
XIV ~1242 
PO2
-
 asymmetrical 
stretching 
DNA, RNA, phospholipid, 
phosphorylated protein 
XV ~1200 
PO2
- asymmetrical 
stretching 
Phosphate I 
XVI ~1092 
PO2
-
 symmetrical 
stretching 
DNA, RNA, phospholipid, 
phosphorylated protein 
XVII ~1062 C-O stretching DNA and RNA ribose 
XVIII ~1008 C-O stretching DNA deoxyribose 
XIX ~966 
C-O stretching, C-C 
stretching 
DNA deoxyribose 
Table 8 Spectral assignments of control and PCa samples, based in the information presented in Table 7.(164, 189) 
With the spectral analysis was possible to identify in all spectra of control and PCa samples the 
contributions of proteins, lipids, carbohydrates and nucleic acids DNA and RNA present in the 
prostate tissue samples.  
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At first glance the control and PCa spectra of both patients (aggressive and less aggressive 
tumour) seem similar, as almost all assign bands are observable in all spectra – see Table 8. 
However, in a closer look, differences between the control and PCa spectra can be detected, 
mainly differences in the band intensities. And, analysing both Figures 15 and 16, we detect that 
these differences are much more evident in the spectra of the patient with an aggressive tumour 
than in the spectra of the patient with a less aggressive tumour.  
The two major bands, which are common for all control and PCa spectra, are the Amide I and 
Amide II, characterizing the spectrum of proteins. Amide I at 1645 cm-1 identifies the C=O 
stretching mode and Amide II at 1548 cm-1 refers to the combination of both N–H bending and 
C–N stretching. As already mentioned, Amide I and II not only identify protein molecule but their 
positions and shapes reflect the secondary protein structure adopted by the polypeptide chain, 
reflecting the backbone conformation and hydrogen-bonding pattern.(192, 194) The Amide III is 
also observable at 1310 cm-1 attributed mainly to N-H bending and C-N stretching. Finally, with 
the water evaporation and the hydrogen-bonded amino groups dominating the region between 
3400 and 3250 cm-1, it is also possible to observe in the spectrum of proteins the Amide A and B 
at 3304 cm-1 and 3094 cm-1, respectively, which are due to N-H stretching – see Table 8.(164, 
192) 
The bands at 2956 cm-1 and 2926 cm-1 attributed to asymmetrical CH3 and CH2 stretching, 
respectively, are present in all spectra and identify the present of lipid molecules – see Table 8. 
However, there are two bands of the spectrum of lipids at 2878 cm-1 and ~2852 cm-1 due to 
symmetrical CH3 and CH2 stretching, respectively, which are only seen in the spectra of control 
samples; while in the spectra of PCa samples a more intense band at 2860 cm-1 probably related 
to symmetrical CH2 stretching is observed.(192, 194) Moreover, besides the common present in 
all spectra of the two referred bands, it is evident that they are more intense in the spectra of PCa 
samples in both patients – see Figures 15 and 16. It is known that, usually, in biological 
tissues/cells there are a greater number of methylene groups in phospholipids (lipids of the 
membrane that contain phosphorus), so the intensity of the CH2 absorptions is 10-20 times that of 
the corresponding CH3 absorption.(202) These differences can be detected in the spectra of 
control samples. In the spectra of PCa samples is possible to verify an increased disorder of the 
methylene chains of membrane lipids, which results in the presence of a more intense band at 
~2860 cm-1 possibly related to symmetrical CH2 stretching that overlaps the bands at 2878 cm
-1 
and ~2852 cm-1 related to symmetrical CH3 and CH2 stretching, respectively. (202, 204)  
The presence of lipids is supported by the bands at 1464 cm-1 and 1450 cm-1 attributed to CH2 
and CH3 bending, respectively.(164) 
The band at 1750 cm-1 due to C=O stretching also supports the presence of lipid molecules and 
its observed higher intensity in the PCa spectra, which is much more evident in the patient with 
an aggressive tumour, also supports the hypothesis of a disorder in the membrane lipids related 
to the presence of prostate cancer and suggests that this disorder is in a more advanced stage in 
patients with a more aggressive tumour – see Figures 15 and 16.(164, 192) 
Finally, in the “fingerprint region” is possible identify C-O-C, C-O, C-C, C-O-P, P-O-P vibrations of 
DNA, RNA, carbohydrates, lipids and proteins. This region presents some specific signatures that 
enable its rapid identification, however in complex biological samples such as prostate tissue 
these features are difficult to observe.(189, 192) It was possible to assign some bands common 
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for all spectra, such as the bands at 1372 cm-1 and 1362 cm-1 due to C-N stretching of cytosine 
and guanine. The asymmetrical and symmetrical PO2- stretching at 1242 cm-1 and at 1092 cm-1, 
respectively, suggest the absorption of O–P=O linkages of the polynucleotide chains in DNA and 
RNA. The band at 1200 cm-1 due to asymmetrical PO2- stretching is related to phosphate I.  The 
bands at 1062 cm-1 and at 1008 cm-1 are attributed to C-O stretching of DNA/RNA ribose and 
DNA deoxyribose, respectively, and the band at 966 cm-1 is due to C-O and C-C stretching of DNA 
deoxyribose – see Table 8.(164, 192) 
 
The direct spectral interpretation reveals some differences between control and PCa samples and 
between patients and has suggested some hypothesis about the spectral regions and compounds 
that can be used to distinguish between the control and PCa samples and between PCa samples. 
However, this analysis is not sufficient to accomplish the proposed goals of identify and 
characterize prostate tissues.  
The visual spectral interpretation has been the backbone of spectroscopic analysis since the 
establishment of spectrometers but it can be highly subjective, particularly in modern 
spectroscopy, where a huge amount of spectral data is collected by FTIR. Pattern recognition 
techniques are now applied to infrared data with the attempt to remove subjectivity and allow 
realistic processing of large datasets.(189, 192) Therefore, the technique multivariate analysis was 
used to highlight differences between the study patients and between the study groups (control 
and PCa). 
 
10. Multivariate Analysis 
 
10.1. Results and Discussion 
Principal Component Analysis (PCA) was applied to the mid-infrared spectra of prostate samples 
in order to extract the main sources of variability and specific spectral regions were chose 
according to some characteristics related to cancer detection that are possible to identify with 
FTIR spectroscopy – see Table 7. PCA was applied to the chosen regions at ranges of 3800-3600, 
3000-2800, 1800-900, 1500-900, 1300-900, 1200–900 and 1800-1700 cm-1. As previously 
mentioned in chapter 2, the two spectral pre-treatment procedures applied in the chosen spectral 
regions were Standard Normal Deviates (SNV) and second order Savitsky-Golay derivative (2D). 
After testing both data pre-treatments the second order Savitsky-Golay derivative 2D was the one 
used in all the spectral regions presented below.  
The region at 3800-3600 cm-1 was tested, despite there was no initial assumption about 
relevant information to cancer detection in this region – see Table 7. Since it showed no 
discrimination capable to be explained according to the known sample characterization, the 
results for this region are not presented. The regions 1800-900, 1500-900 and 1300-900 cm-1 were 
also tested as they could give relevant information (Table 7), mainly about lipid metabolism 
alterations (1800-1700 cm-1), protein alterations due to increased hypomethylation (1500-1400 
cm-1), as well as alterations in the backbone of the nucleic acids and in the glycogen content 
(1300-900 cm-1). Despite the fact these regions are very information rich and already show some 
tendency to form two main groups, these results are also not presented. Their loadings proved to 
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be noisy and very difficult to interpret, and the separation of groups could be better, as the 
samples still seem a little shuffled. These large range spectral regions do not reveal much relevant 
information to the aim of the study. Therefore, it seems necessary to reduce the spectral regions 
and test smaller and more specific spectral ranges according to the assumptions presented in 
Table 8 and also taking in account the hypothesis suggested by the direct spectral analysis.   
Mid-IR region 3000-2800 cm-1 
To test the hypothesis of an increased disorder of the methylene chains of membrane lipids 
associated with the PCa samples, PCA was applied to the region 3000-2800 cm-1, which 
correspond to the lipid region that includes the C-H, CH3, CH2 stretching of lipids and also proteins 
– see Figure 17. (164) 
 
 
Figure 17 PCA scores (a) and loadings (b) of control and PCa samples at 3000-2800 cm-1 range.  
Two main groups may be suggested based on the distribution of the samples along PC1, which 
explains most of the variability. PC2, which could explain the second most important factor of the 
remaining analysis, do not seem to affect the groups’ distribution and, therefore, it had not been 
taken in account in the loadings interpretation.   
It can be observed one group of control samples (gC), which is mainly explained by the positive 
side of PC1 and, wherefore, distributed in Q1 and Q4.  It is constituted by almost all control 
samples, except C2 and C5. The other group is mainly explained by the negative side of PC1 and 
distributed in Q2 and Q3. This group of PCa samples (gPCa) includes T1, T2, T4, T5, T6 and T7. The 
two control samples C2 and C5 are also included in this group. The PCa samples T3 and T8 are not 
included in the gPCa, however they are distributed close to zero of PC1, which indicates they are 
less affected by the peaks identified in PCA loadings. The assignments of the peaks selected in the 
PCA loadings (Figure 17b) are shown in Table 9.  The analysis of the loadings is useful to 
understand the basis of the samples distribution in the PCA scores (Figure 17a).  
 
Bands (cm-1) PC1 Assignments Group 
~2986 + C-H stretching gC 
~2960 - Asymmetric CH3 stretching of lipids and fatty acids gPCa 
~2952 + Asymmetric CH3 stretching of acyl chains (lipids) gC 
~2933 - C-H stretching band in malignant tissues gPCa 
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~2916 + C-H stretching band in normal tissues gC 
~2898 + Symmetric CH3 stretching of acyl chains (lipids) gC 
~2872 - Symmetric CH3 stretching gPCa 
~2852 + Symmetric CH2 stretching of acyl chains (lipids) gC 
~2836 - N-H stretching (NH3
+) gPCa 
~2812 + N-H stretching (NH3
+) gC 
Table 9 Mid-IR bands at range 3000-2800 cm-1 identified in PCA loadings.(164, 192, 194) 
The analysis of the PCA scores showed that control samples C1, C3, C4, C6, C7 and C8 are close to 
each other, suggesting the formation of a group (gC) mainly explained by the positive side of PC1.   
The distribution and proximity of these control samples is justified by six peaks identified in the 
PCA loadings profile (2986, 2952, 2916, 2898, 2852 and 2812 cm-1). The peak at 2986 cm-1 is an 
unspecific peak related to the C–H stretching vibration characteristic of this region. The peaks at 
2952, 2898, 2852 cm-1 are related to asymmetric and symmetric CH3 stretching and symmetric CH2 
stretching of the acyl chains of lipids, respectively. The peak at 2916 cm-1 is related to a band 
characteristic of normal tissues, due to C-H stretching. The peak at 2812 cm-1 is related to the N-H 
stretching of the NH3
+. As there is another peak with the same assignment in the negative side of 
PC1 (2836 cm-1), and so even related to the opposite group, these two peaks do not seem to 
justify the formation of the groups. (164, 192) 
The analysis of the PCA scores also suggested the formation of another group (gPCa), which is 
explained by the negative side of PC1 and include the PCa samples T1, T2, T4, T5, T6 and T7. Four 
peaks identify in the PCA loadings can justify the proximity of these samples and the formation of 
this group:  the peak at 2960 cm-1 due to asymmetric CH3 stretching of lipids and fatty acids may 
suggest differences in fatty acids related to the gPCa, that can be in high concentration or 
modified; the peak at 2933 cm-1 is related to a band only present in malignant tissues; the peak at 
2872 cm-1 is an unspecific peak related to symmetric CH3 stretching and the already refereed peak 
at 2836 cm-1 is related to the N-H stretching of the NH3
+.(164) 
As already mentioned, the region 3000-2800 cm-1 is the lipid region and includes the stretching 
vibrations of CH2 and CH3 of phospholipids, cholesterol and creatine, which are compounds that, 
according to the literature, are higher in normal tissues.(164) Therefore, the identification in this 
region of a higher number of peaks (six) related to the gC was expected and suggest a higher 
content of these compounds in the control samples in comparison to the PCa samples.  
Moreover, the PCA analysis also corroborates the hypothesis of an increased disorder of the 
methylene chains of membrane lipids associated with the gPCa. Notice that a band related to the 
asymmetric CH2 stretching of acyl chains of lipids, which is usually at 2926-2931 cm
-1, was not 
identify in the PCA loadings, probably because of the appearance of a peak at 2933 cm-1 
characteristic of malignant tissues, which suggest a disorder in membrane methylene chains.(164, 
202) Other authors have already concentrated their studies on examining the spectral 
characteristics of prostate tissue in the region 3000-2800 cm-1. They have also performed a 
quantitative analysis and have concluded that by using the CH2/CH3 ratio it was possible to 
differentiate between normal and cancerous tissues using FTIR, suggesting a membrane lipid 
disorder related to the malignant tissues.(202, 204) As the cancer cells divide rapidly, the new 
membrane biogenesis also has to occur rapidly, which may result in differences in the membrane 
synthesis and lead to the suggested disorder of the chains of membrane lipids.  
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The suggested alterations in fatty acids in the gPCa can also be related to an accelerated cancer 
cells division, which can lead to an increased fatty acid synthesis.(205) These alterations are 
further investigated in the PCA analysis of the region 1800-1700 cm-1.  
The PCa samples T3 and T8 are out of pattern and are not included in the gPCa. As they are 
located close to zero, they are less affected by the peaks identified in PCA loadings, which may 
indicate that the identified alterations characteristics of the gPCa are not yet present in these 
patients; they may be in a more initial stage of PCa where a membrane lipid disorder is not yet 
evident.   
The two control samples, C2 and C5, included in the gPCa are control samples of patients with 
aggressive tumours. Therefore, their localization close to the PCa samples, especially C2 that is 
very close to T2, may be a result of errors in the sample collection. These errors may lead to the 
collection of PCa tissue along with the collection of the normal prostate tissue for these control 
samples.  
Mid-IR region 1200-900 cm-1 
PCA was applied to the region 1200-900 cm-1, which correspond to the phosphodiester region, 
including the phosphodiester stretching bands for absorbances due to glycogen – see Figure 
18.(164) 
 
 
Figure 18 PCA scores (a) and loadings (b) of control and PCa samples at 1200-900 cm
-1
 range. 
In this region is also possible to identify in the PCA scores (Figure 18a) two groups based, in this 
case, on the distribution of the samples along PC2. PC1 do not seem to affect the groups’ 
distribution and, therefore, it had not been taken in account in the loadings interpretation.  
Again, one group of control samples (gC) can be observed, which is mainly explained by the 
negative side of PC2 and distributed in Q3 and Q4.  It is constituted by almost all control samples, 
with the exception again of C5. The group of PCa samples (gPCa) is mainly explained by the 
positive side of PC2 and distributed in Q1 and Q2. This group includes T1, T2, T3, T4, T5, T6 and 
T7. The control sample C5 is also included in this group and the PCa sample T8 are again not 
included. Table 10 shows the assignments of the peaks selected in the PCA loadings (Figure 18b). 
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Bands (cm-1) PC2 Assignments Group 
~1189 - Deoxyribose gC 
~1173 + C-O stretching in malignant tissues gPCa 
~1168 - 
C-O stretching in normal tissues; 
C-O stretching of C-OH groups of serine, threosine and tyrosine 
of proteins 
gC 
~1156 + C-O stretching of proteins and carbohydrates gPCa 
~1149 - 
Glycogen absorption due to C-O and C-C stretching and C-O-H 
deformation 
gC 
~1128 + Symmetric phosphodiester stretching of RNA gPCa 
~1116 - Symmetric P-O-C stretching gC 
~1108 + Symmetric P-O-C stretching gPCa 
~1092 - 
Symmetric PO2-  stretching (phosphate II); Symmetric PO2 
stretching of RNA and DNA; Symmetric stretching of phosphate 
groups in phospholipids 
gC 
~1080 + 
Symmetric PO2-  stretching of RNA and DNA; Phosphate I in RNA 
(one of the triad peaks of nucleic acids (along with 1060 and 
1030) 
gPCa 
~1060 + 
C-O stretching of deoxyribose (one of the triad peaks of nucleic 
acids) 
gPCa 
~1045 + 
C-O stretching coupled with C-O bending frequencies of the C-
OH groups of carbohydrates (glucose, fructose, glycogen, etc); 
Glycogen band 
gPCa 
~1030 + 
C-O stretching coupled with C-O bending (one of the triad peaks 
of nucleic acids) 
gPCa 
~1024 - C-O stretching associated of glycogen gC 
~964 + 
C-C and C-O stretching in deoxyribose of DNA in malignant 
tissues 
gPCa 
~954 - C-C  and C-O stretching of deoxyribose gC 
~934 + Left-handed helix DNA gPCa 
Table 10 Mid-IR bands at range 1200-900 cm-1 identified in PCA loadings.(164, 192, 194) 
The analysis of the PCA scores at the region 1200-900 cm-1 approximates the samples C1, C2, C3, 
C4, C6, C7 and C8, proposing the constitution of the group of control samples, gC, explained by 
the negative side of PC2. Seven peaks identified in the PCA loadings characterize this group: the 
peaks at 1189 cm-1 and 954 cm-1 are due to C-C and C-O stretching of deoxyribose; the peak at 
1168 cm-1 is related to the C-O stretching of the C-OH groups of serine, threosine and tyrosine of 
proteins and hydrogen-bonded stretching of the C-OH groups, this is a C-O stretching band only 
present in normal tissues; two peaks associated to C-O and C-C stretching and C-O-H deformation 
of the glycogen at 1149 cm-1 and 1024 cm-1; the peak at 1116 cm-1 is due to symmetric P-O-C 
stretching, as there is another peak with the same assignment and related to the opposite group 
in the positive side of PC2 (1108 cm-1), these to peaks do not seem to justify the formation of the 
groups; finally the peak at 1092 cm-1 related to symmetric PO2- stretching of phosphate II, 
symmetric PO2- stretching of RNA and DNA and symmetric stretching of phosphate groups in 
phospholipids. (164, 192) 
The positive side of PC2 in the PCA scores suggest the formation of the group of PCa samples, 
gPCa, which includes the samples T1, T2, T3, T4, T5, T6 and T7. The distribution of the gPCa is 
justified by ten peaks identified in the PCA loadings (1173, 1156, 1128, 1108, 1080, 1060, 1045, 
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1030, 964 and 934 cm-1). The peak at 1173 cm-1 is a C-O stretching band only present in malignant 
tissues. The peak at 1156 cm-1 is due to C-O stretching of proteins and carbohydrates and the 
peak at 1128 cm-1 is due to symmetric phosphodiester stretching of RNA. The already refereed 
peak at 1108 cm-1 is related to symmetric P-O-C stretching. The peaks 1080, 1060 and 1030 cm-1 
are the triad peaks of nucleic acids; the first one is related to symmetric PO2- stretching of RNA 
and DNA (phosphate I in RNA), the second is due to C-O stretching of deoxyribose and the last one 
is due to C-O stretching coupled with C-O bending. The peak at 1045 cm-1 is a glycogen band and is 
related to C-O stretching coupled with C-O bending frequencies of the C-OH groups of 
carbohydrates.  The peak at 964 cm-1 is a band characteristic of malignant tissues and is due to C-C 
and C-O stretching in deoxyribose of DNA. Finally, the peak at 934 cm-1 is related to the left-
handed helix of the DNA.(164, 192) 
It has been previously suggested by other authors that the glycogen content can be used to 
differentiate benign from malignant tissues.(201, 204) Cancer cells have a high metabolic turnover 
and use up all the glucose for their fast replication. Thus, there is no storage of excess glucose as 
glycogen and lower glycogen content is characteristic of malignant tissues in comparison to 
normal tissues.(204) The identification in the PCA loadings of two glycogen bands at 1149 cm-1 
and 1024 cm-1 associated with the gC and of only one glycogen band at 1045 cm-1 associated with 
the gPCa support this hypothesis, suggesting a higher glycogen content in the control samples 
than in the PCa samples.  
 Furthermore, in cancer cells, the nuclear compaction reduces due to decrease in hydrogen 
bonding in DNA, leading to increased nucleus/ cytoplasm ratio.(204) The identified band at 1080 
cm-1, due to symmetric PO2- stretching of RNA and DNA, characterized the gPCa (positive side of 
PC2) and is a band that suggests this increase in the nucleic acids in malignant tissues.  
Out of pattern sample T8: The sample T8 is included in the gC and is a PCa sample of a patient 
with a less aggressive tumour. Its location in the gC may indicate that the identified alterations 
characteristics of the gPCa are not yet present in this patient. 
The control sample C5 is again included in the gPCa. Its localization again close to the PCa samples 
intensify the possibility of errors in the sample collection, which lead to the collection of PCa 
tissue along with the collection of the normal prostate tissue for this control sample.   
Mid-IR region 1800-1700 cm-1 
The region 1800-1700 cm-1 corresponds to the region of the fatty acid esters. Also includes the 
range 1715-1700 cm-1, which corresponds to the region of the bases.(164) PCA was applied to this 
specific region also to test again the hypothesis of a lipid disorder, but mostly to explore the 
observances of the direct spectral analysis that highlight a band near 1750 cm-1, related to C=O 
stretching, which is more intense in the PCa spectra and its higher intensity is much more evident 
in the spectra of patients with more aggressive tumours - see Figure 19. 
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Figure 19 PCA scores (a) and loadings (b) of control and PCa samples at 1800-1700 cm-1 range. 
Based on the distribution of the samples along PC1, which explains most of the variability, two 
main groups may be identified. However, PC2, which explains about 25% of the variability, also 
seems to affect the samples distribution, mainly the positive side of PC2 that seems to explain the 
distribution of the three PCa samples T2, T5 and T6 distributed in Q1 and the control sample C5 
distributed in Q2 – see Figure 19a. Therefore, in a first analysis the examination of the PCA 
loadings was only based on the PC1 distribution to form the two main groups. After this first 
interpretation another one based on the PC2 distribution was made. 
Based on the distribution of the samples along PC1, one group of only PCa samples (gPCa) can be 
observed, which is mainly explained by the positive side of PC1 and located in Q1 and Q4. The 
other group is constituted with only control samples (gC) and is mainly explained by the negative 
side of PC1 and distributed in Q2 and Q3. The PCa sample T7 are not included in any group as it is 
distributed close to zero of both PCs, which indicates it is not affected by the peaks identified in 
PCA loadings. Noticed that the control sample C5, despite being on the negative side of PC1 as all 
control samples, it is located alone in Q2 and not close to the other control samples. The 
assignments of the PC1 peaks selected in the PCA loadings (Figure 19b) are shown in Table 11. 
   
Bands (cm-1) PC1 Assignments Group 
~1758 + C=C stretching of  lipids and fatty acids gPCa 
~1750 - 
Ester C=O stretching of triglycerides, C=O stretching of 
polysaccharides 
gC 
~1746 + 
C=O stretching of lipids, Ester C=O stretching of 
phospholipids 
gPCa 
~1740 - C=O stretching of polysaccharides gC 
~1732 + C=O stretching of the fatty acid ester band gPCa 
~1722 - C=O stretching gC 
~1714 + 
C=O stretching of DNA and RNA, C=O stretching of purine 
base, C=O stretching of thymine 
gPCa 
Table 11 Mid-IR bands at range 1800-1700 cm-1 identified in PCA loadings, only based in PC1 distribution.(164, 192, 194) 
In the region 1800-1700 cm-1 all the control samples are in the negative side of PC1 in the PCA 
scores, forming a group, gC, whose distribution is explained by three peaks in the PCA loadings – 
see Table 11. The peak at 1750 cm-1 due to ester C=O stretching of triglycerides and C=O 
stretching of polysaccharides and the peak at 1740 cm-1 also due to C=O stretching of 
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polysaccharides. The peak at 1722 cm-1 is an unspecific peak related to the C=O stretching 
vibration characteristic of this region.(164, 192) 
The analysis of the PCA scores also showed that all the PCa samples form a group, gPCa, mainly 
explained by the positive side of PC1. Four peaks identify in the PCA loadings justify the formation 
of this group: the peak at 1758 cm-1 due to C=C stretching of lipids and fatty acids; the peak at 
1746 cm-1 due to C=O stretching of lipids and ester C=O stretching of phospholipids; the peak at 
1732 cm-1 due to the C=O stretching of the fatty acid ester band; and finally the peak at 1714 cm-1 
related to C=O stretching of DNA and RNA, C=O stretching of purine base and C=O stretching of 
thymine.(164, 192) 
The role of lipid metabolism has gained particular interest in prostate cancer research. Many 
studies have already outlined the unique upregulation of de novo lipid synthesis in prostate 
cancer.(205-207) Besides the lipogenic phenotype, there is also a metabolic shift in which cancer 
cells use alternative enzymes and pathways to facilitate the production of fatty acids. The new 
synthesized lipids can support a number of cellular processes to promote cancer cell proliferation 
and survival.(205) 
Cancer cells are characterized by a large number of metabolic alterations and the shift from 
catabolic to anabolic metabolism is a hallmark of cancer cells. Normally, by the catabolic pathway, 
each molecule of glucose consumed by a cell is metabolized through glycolysis to two molecules 
of pyruvate. Pyruvate is then converted to acetyl-CoA in the mitochondria where it enters the 
tricarboxylic acid (TCA) cycle to produce redox substrates for oxidative phosphorylation. In cancer 
cells a unique phenomenon of aerobic glycolysis occurs, whereby they consume a large quantity 
of glucose, metabolize it via glycolysis, and release the majority as lactic acid into the extracellular 
space, under normal oxygen conditions.(206, 207) 
Therefore, cancer cells seem to consume an excessive quantity of glucose. They utilize it 
catabolically but also anabolically, whereby the carbons are used as a source to synthesize and 
fulfil the macromolecular demand of their proliferative phenotype.(205) Thus, lower 
polysaccharide (glucose) content is expected in malignant tissues. The identified peaks at 1750 
cm-1 and 1740 cm-1, due to C=O stretching of polysaccharides, characterized the gC (negative side 
of PC1) and suggest this higher polysaccharide content in the control samples in comparison to 
the PCa samples.  
Furthermore, with the exception of brain, liver, adipose and lung tissues, fatty acid synthesis in 
normal and differentiated adult cells is relatively low. In the other tissue types, cells utilize 
circulating fatty acids derived from dietary sources to fulfil their fatty acid requirements. 
However, it is now recognized that cancer cells exhibit increased production of de novo fatty 
acids. Because of the fast division of cancer cells, one major purpose for increased fatty acid 
synthesis is to supply the heavy demand for new membrane biogenesis.(205, 207) Swinnen et al. 
already demonstrated that de novo fatty acids used for membrane biogenesis also preferentially 
localize in the membrane’s signaling raft domains. Thus, de novo fatty acids may play a significant 
role in propagating oncogenic signals from the plasma membrane.(205) 
The peak at 1758 cm-1 due to C=C stretching of lipids and fatty acids and the peak at 1732 cm-1 due 
to the C=O stretching of the fatty acid ester band, which characterized the gPCa (positive side of 
PC1), suggest an increased content in fatty acids in the PCa samples.  
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Out of pattern patient T7: the PCa sample T7 is not included in any group and as it is distributed 
close to zero of both PCs, it is not affected by the peaks identified in PCA loadings. Accordingly to 
the sample histopathological information the patient number 7 is the only one with an Eco 
showing benign prostatic hyperplasia (BPH). Also this patient initiated 3 months before surgery an 
androgen deprivation therapy (Casodex). These characteristics may have affected the tumour 
tissue content and cause the out of pattern distribution of this sample.  
 
With the attempt to characterize the three samples T2, T5 and T6 and the control sample C5, the 
PC2 peaks selected in the PCA loadings (Figure 19b) were assigned and are presented in Table 12.   
 
Bands (cm-1) PC2 Assignments 
~1750 + Ester C=O stretching of triglycerides; C=O stretching of polysaccharides 
~1734 + Fatty acid ester band 
~1728 - C=O band 
~1722 + C=O stretching 
~1714 - 
C=O stretching of DNA and RNA, C=O stretching of purine base, C=O 
stretching of thymine 
Table 12 Mid-IR bands at range 1800-1700 cm-1 identified in PCA loadings, only based in PC2 distribution.(164, 192, 194) 
Based in the PC2 distribution, three peaks characterizing the group T2, T5, T6 and the sample C5 
(positive side of PC2) can be identified in the PCA loadings: the peak at 1750 cm-1 due to ester C=O 
stretching of triglycerides and C=O stretching of polysaccharides, the peak at 1734 cm-1 related to 
the fatty acid ester band and the unspecific peak at 1722 cm-1 related to C=O stretching.(164)  
Unfortunately, this new PCA analysis of the PC2 distribution do not give much more new 
information to the characterization of the group T2, T5 and T6, which accordingly to the sample 
histopathological information are the three more aggressive tumours.  
Out of pattern sample C5: peaks at 1750 cm-1 and 1722 cm-1 present in PC2+ are also present in 
the negative side of PC1, thus, they seem to be more related to the distribution of the sample C5 
– see Table 12. The sample C5 has always behaved as an out of pattern sample in the previous 
PCA analysis performed in this study. Therefore, besides the identified peaks do not helped much 
in the characterization of this sample, there is a strong possibility that this is actually a sample of 
PCa tissue from the patient number 5, and not a sample of normal prostate tissue. Accordingly to 
the histopathological information the tumour of the patient number 5 is extremely aggressive, 
occupying large part of the prostate, thus, it is highly possible that a less developed part of the 
tumour was collected as being normal prostate tissue of the patient.  
Another PCA analysis at the range 1800-1700 cm-1 was performed without the samples T2, T5 
and T6. This analysis was performed in order to test if the contribution of this group of patients 
with more aggressive tumours were somehow affecting the others samples distribution and 
therefore masking some important characteristics. The PCA results are shown in Figure 20. 
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Figure 20 PCA scores (a) and loadings (b) of control and PCa samples at 1800-1700 cm-1 range (without T2, T5 and T6) 
With this new analysis is possible to identify again the two initially proposed groups (gPCa and 
gC). The disposition of both groups was not affected, as the distribution of the PCa samples (gPCa) 
is still explained by the positive side of PC1 and located in Q1 and Q4; and the distribution of the 
control samples still mainly explained by the negative side of PC1 and distributed in Q2 and Q3. 
The PCa sample T7 still not being included in any group and the control C5 still located in Q2, 
distant from the other control samples. The loadings profile remains the same and the 
distribution of both groups still justified by the same peaks already analyzed above. Therefore, we 
can conclude that the PCa samples T2, T5 and T6 were not significantly affecting the other 
samples distribution at the range 1800-1700 cm-1. 
    
Finally, another PCA analysis of only PCa samples was also performed at the range 1800-1700 
cm1, with the attempt to classify and characterize the PCa samples, taking in account the clinical 
and histopathological information about the patients – see Table 6, chapter 2. The PCA results are 
shown in Figure 21. 
 
 
Figure 21 PCA scores (a) and loadings (b) of the PCa samples at 1800-1700 cm
-1
 range. 
In a first analysis of the PCA scores the distribution of the samples T2, T5 and T6 alone in Q2, 
being explained by the negative side of PC1 and the positive side of PC2, is highlighted. The 
assignments of the peaks selected in the PCA loadings (Figure 21b) are shown in Table 13. 
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Bands (cm-1) PC1 PC2 Assignments 
~1758 - + - C=C stretching of  lipids and fatty acids 
~1750 + - + 
Ester group C=O stretching of triglycerides; C=O stretching of 
polysaccharides 
~1746 + - 
C=O stretching of lipids, Ester C=O stretching of 
phospholipids 
~1734 - + Fatty acid ester band 
~1732 + + - C=O stretching 
~1728 + - - C=O band 
~1725 - + C=O stretching of the fatty acid ester band 
~1714 + + - 
C=O stretching of DNA and RNA, C=O stretching of purine 
base, C=O stretching of thymine 
Table 13 Mid-IR bands at range 1800-1700 cm-1 identified in PCA loadings of the PCa samples.(164, 192, 194) 
Two peaks identified in the PCA loadings can unequivocally characterize the samples T2, T5 and 
T6: the peak at 1734 cm-1 related to the fatty acid ester band and the peak at 1725 cm-1 due to 
C=O stretching of the fatty acid ester band.(164) 
This PCA analysis of only PCa samples support the hypothesis of a lipid disorder characteristic of 
PCa tissue samples.  Furthermore, the two peaks that explained the distribution of the samples 
T2, T5 and T6 suggest an increased content in fatty acids in these PCa samples, which may 
indicate that these more aggressive tumours have a more demanding proliferation rate and, 
therefore, require more de novo synthesis of fatty acids in comparison to the samples of patients 
with less aggressive tumours (T3, T7, T8).  
However, the results of the PCA analysis of only PCa samples at the range 1800-1700 cm-1 do not 
give enough information and an in-depth classification of the PCa samples has not been possible.   
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F. Conclusions 
With the direct analysis of the spectra the main bands of the spectra of control and PCa samples 
between 4000-600 cm-1 were assigned. This analysis shows some distinction between control and 
more aggressive PCa samples, as it allows the identification of perceptive differences between the 
spectra, mainly in the lipid region. Thereby, besides not being sufficient to distinguish the spectra 
of control samples from the spectra of PCa samples, the direct spectral interpretation suggested 
some important hypothesis about spectral regions and compounds that orientate and support the 
multivariate analysis.  The complexity associated to biological tissues, which lead to the overlap of 
important bands in the IR spectra, along with the highly dimensional data of this study, makes 
mandatory that an appropriate multivariate analysis was performed. 
The multivariate analysis reveals important differences between control and PCa samples. The 
PCA analysis of three spectral regions (3000-2800 cm-1, 1200-900 cm-1, 1800-1700 cm-1) suggested 
the formation of two groups, a group of control samples and a group of PCa samples, according to 
the biochemical modifications characteristics of each region. The analysis of the PCA loadings 
profiles of the three regions propose that prostate cancer tissues can be probably identify and 
distinguished from normal prostate tissues based on dysregulations in lipid metabolism, mainly a 
higher content in fatty acids and  an increased disorder of the chains of membrane lipids. Also a 
lower polysaccharide (glucose) and glycogen content and an increase in the nucleic acids seem to 
characterize the PCa tissues, which are pathologic findings expected in malignant tissues. 
The attempt to classify and distinct between PCa tissues has not been accomplished, as the small 
sample size do not give enough information and an in-depth classification has not been possible. 
The best FTIR conditions for the analysis of tissues have been established: spectra was acquired in 
the 4000 to 900 cm-1 range at 8 cm-1 resolution with 64 co-added scans at a room temperature of 
± 25ºC and humidity ± 37%. No tissue preparation or fixation influenced the procedure, the 
radical prostatectomy specimens stored at -80ºC were thawed at room temperature and placed 
onto the crystal, fully covering it, and during the spectral acquisition all the samples experienced 
the same constant pressure, increasing the adhesion to the crystal and decreasing the spectral 
artifacts. The tissue drying was performed by allowing water to evaporate from the sample with 
the acquisition of six spectra (replicas) for each tissue sample and the three last replicas, which 
have reached the maximum drying stage, were the ones used in the multivariate analysis. Radical 
prostatectomy pieces have been identified as a potential gold standard specimen for FTIR 
prostate tissue analysis. 
The biological relevance of the results has been affected by the small sample size; however, there 
is no doubt that this pilot study served as a first step to caught the attention and the interest for 
further confirmatory investigations in the future. Prostate cancer diagnostic strategies must 
evolve and FTIR has clearly demonstrated in this study that it is a powerful bioanalytical technique 
which when associated with appropriate statistical data analysis methods, such as different 
multivariate analysis techniques, has the ability to discriminate prostate cancer tissue from 
normal prostate tissue. The FTIR analysis has proved to be robust and versatile and can enable 
moving toward diagnosing neoplastic changes at progressively earlier stages. Furthermore, this 
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pilot study reveals the potential of FTIR to be used as a pathology laboratory tool as it seems to be 
an ideal diagnostic test that would provide rapid, non-invasive diagnosis at the point-of-care with 
high throughput and without prior tissue processing. 
 
G. Limitations and Future Remarks 
The promising findings of this pilot study merited further investigation of FTIR in tissue studies 
and it is clear that the challenges of achieving a universal FTIR classification model are significant. 
A thorough understanding of how FTIR may discriminate between prostate tissues is still 
necessary to judge its clinical niche and thus requires an increase in the sample size to continue.  
The prostate tissue characterization based on the histopathology is subjective, which makes the 
diagnosis of prostate cancer in individual patients to be problematic. This subjectivity associated 
with the histopathological sample characterization along with the possibility of sampling errors, 
may have restricted and awry orientate this study. Furthermore, prostate tissue is 
characteristically heterogeneous which may have led to the overlap of important FTIR absorptions 
and masked important biochemical changes of the spectral dataset. Therefore, future 
experiments validated with an independent and unequivocally classified data set are necessary to 
deeply understand and identify the molecular changes that may precede the morphological 
changes, thus enabling earlier diagnosis of prostate cancer. Also a closer approach to analyse 
specific molecules demonstrated to be associated with prostate cancer, such as fatty acids and 
glycogen, should be conducted. The results could be supplement with more specific 
metabolomics techniques, such as Mass Spectrometry or Tissue Microarrays.  
In order to further enhance the credibility of FTIR analysis and its potential for automation, the 
next challenge is to pursue future investigations with the attempt to create a FTIR spectral and 
biochemical representation of a whole prostate, including all the pathology contained within the 
specimen. It could be possible with the association of a microscope to the FTIR equipment. The 
application of vibrational microspectroscopy will enable fine detail analysis of prostate tissue 
allowing new investigations, such as the correlation of the FTIR spectra of prostate tissue with 
Gleason score and clinical stage of the PCa at the time of biopsy. 
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